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ABSTRACT
Creatine is one of the most frequently or generally used ergogenic substances. It 
is used by professional and amateur athletes and the “man on the street”. 
Creatine is involved in energy production and protein synthesis in muscle. 
Although studies have been carried out on the effect of creatine on adults, no 
study has yet determined whether creatine would have an influence on the 
developing rat foetus if taken by a female during pregnancy.
The aim of this study was thus to determine whether creatine had an effect on 
the developing foetus.
Dams were divided into two groups, which were injected between days 7-13 and 
on days 9 and 11 only of intra-uterine development respectively. Each group was 
subdivided into a control and two experimental groups. Experimental group one 
received a low dose of creatine (53.5mg/250g body weight); the other 
experimental group received a high dose of creatine (107mg/250g body weight). 
The control group received an equal volume (1ml) of the vehicle (saline) in which 
the creatine was constituted. Dams were sacrificed on day 20 of development. 
The foetuses were removed and their weight and length taken. Foetuses were 
examined for abnormalities. Two foetuses from each litter underwent skeletal 
staining. Tissue was excised from the remaining foetuses and processed for 
histology for histological investigation.
Creatine positively affected the growth of the foetuses of dams injected between 
days 7-13, while foetuses of dams injected only on days 9 and 11 in the B-group 
showed reduced growth. Creatine also had a slightly negative effect on the 
histological structure of the liver, but enhanced skeletal muscle growth, endocrine 
cell formation (pancreas) and skeletal formation.
From the results obtained it is hypothesized that creatine and insulin together 
may play a positive role from implantation to birth, while creatine given at certain 
stages of organogenesis delayed development of the foetus.
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1. INTRODUCTION
Following the discovery of phosphocreatine in 1927 and the metabolic reaction of 
creatine kinase (see section 2.4) in 1934 (Saks et al., 1987; Conway and Clark, 
1996), studies have focused on the biophysiological effect of creatine on muscle 
with specific focus on high-energy demands. Creatine (Greek kreas, flesh) 
metabolism was not studied intensively until recently (1980’s) when a series of 
fascinating discoveries were made. It was demonstrated that creatine analogs 
have the potential to be potent anti-tumour agents (Miller et al., 1993), while 
cyclocreatine exhibits the potential to reduce the damage to a cell that has 
undergone ischemic injury (Saks et al., 1996).
Genetic endowment and proper training are the requirements for an athlete to 
excel in any given sport. Often a combination of physiology and biomechanical 
traits are combined with intense physical and mental training to ensure success 
in sports performance. Due to the increasing pressures and in the hope of 
breaking an elusive record, most athletes (Guzik et al.. 2000) resort to ergogenic 
aids (i.e. substances that improve sport performance beyond the physical effects 
of training)(Wyss and Kadurrah-Daouk, 2000; Persky and Brazeau, 2001), and 
which do not contain pharmacological agents such as nandrolone and anabolic
steroids.
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Creatine is intricately linked in the energy production and utilization reaction, 
which is why 95% of the total creatine content is stored in skeletal muscle 
(Williams et al., 1999; Persky and Brazeau, 2001). Skeletal muscle needs large 
amounts of creatine since it requires huge amounts of ATP to generate energy 
while exercising.
Creatine is phosphorylated to form phosphocreatine (PCr). PCr is used in fast 
and slow twitch muscle fibres, although there are different mechanisms of ATP 
regeneration for each type of muscle. In fast twitch muscle fibres (skeletal muscle 
sprinting) there is a large pool of PCr in the fast twitch muscle. Due to the high 
creatine kinase activity in fast twitch muscle fibres, ADP to ATP regeneration 
(see section 2.4 for metabolic reaction) is kept at near equilibrium during short 
bursts of maximal exercise (Wyss and Kadurrah-Daouk, 2000). These high 
amounts of PCr thus buffer the cytosolic phosphorylation reaction potential that is 
crucial for the proper functioning of regeneration of ATP.
Slow twitch muscle contraction (i.e. the heart), is much more complex than fast 
twitch muscle fibres. Slow twitch myocytes need a continuous supply of 
phosphates to ATP production sites for optimal energy production and utilization 
(Wyss and Kadurrah-Daouk, 2000). Different isoenzymes of creatine kinase 
assist with this particular process. Mitochondrial creatine kinase (Mi- 
CK)(Brudnak, 2004) acts as a transport shuttle to allow creatine to be converted 
to PCr in the intermembranous space of the mitochondrion. ATP that has been
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synthesized in the mitochondrial matrix diffuses into the intermembranous space. 
The y-phosphate group of the ATP molecule is sliced from the ATP by Mi-CK and 
transferred to the creatine to form PCr. The PCr diffuses back into the cytosol to 
the sites of energy utilization (muscle). At the site of energy utilization, ATP is 
dephosphorylated to form ADP. Due to the large amount of PCr available in the 
cytosol, creatine kinase rephosphorilates the ADP back to ATP. This is a time 
saving process, since ADP does not have to diffuse back to the mitochondrial 
matrix to be rephosphorylated to ATP. However, the ATP that was 
dephosphorylated to ADP in the intermembranous space, when Mi-CK sliced off 
the y-phosphate group, diffuses back into the mitochondrial matrix to be
phosphorylated back to ATP (Wyss and Kadurrah-Daouk, 2000).
/
Because creatine is synthesized endogenously in the mammalian body, the 
International Olympic Committee does not classify it as a banned substance. Due 
to the fact that creatine is a nutritional supplement, it is exempted from all the 
rules and regulations set out by the Food and Drug Administration (Breithaupt, 
2001). Athletes that wish to enhance sports performance use creatine as a non­
steroid dietary supplement. Exogenous creatine supplementation can increase 
total creatine concentration in the mammalian body. There is, however, a 
threshold amount of creatine that can be stored in skeletal muscle (see section 
2.4)(Hochachaka and Mossey, 1998). It is due to this attribute that sportsmen 
and sportswomen “load up” on exogenous creatine supplementation. Exogenous 
creatine supplementation improves muscle performance in three ways by:
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1) increasing PCr, 2) increasing PCr resynthesis and 3) decreasing lactic acids 
and adenine nucleotides (Wyss and Kadurrah-Daouk, 2000). The higher the 
concentration of total creatine and phosphocreatine in the skeletal muscle, the 
longer and harder one can exercise.
2. SYNTHESIS AND METABOLIC FUNCTION OF CREATINE
Creatine is synthesized from several amino acids and since it is a natural dietary 
constituent of animal foods, it is considered as non-essential (Campbell, 1995).
2.1 Endogenous synthesis
A normal human being requires about 2 grams of creatine a day (Steenge et al., 
1998; Robinson et al., 2000; Wyss and Kadurrah-Daouk, 2000; Persky and 
Brazeau, 2001; Brudnak, 2004). Fifty percent of creatine (1 gram) is obtained 
exogenously from fish and red meat (Walker, 1979), while Balsom et al. (1993) 
found trace amounts of creatine in plants. The other 50% of creatine is produced 
endogenously.
The amino acids arginine, glycine and methionine play an important role in the 
synthesis of creatine (Campbell, 1995; Persky and Brazeau, 2001). Glycine 
forms the backbone of the creatine molecule while arginine donates its only 
amidino group, and methionine its methyl group (Walker, 1979). The 
amidinotransferase enzyme (AGAT) mainly controls the creatine biosynthesis
4
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reaction, while this reaction is completed by the methyltransferase (GAMT) 
reaction (Williams et al, 1999; Wyss and Kadurrah-Daouk, 2000).
Glycine and Arginine 
▲
AMIDINOTRANSFERASE (AGAT)
Guanidinoacetate and Ornithine
ionine
METHYLTRANSFERASE (GAMT)
Creatine and Adenosylhomocysteine
Figure 1. Biosynthesis of creatine (Williams et al., 1999)
2.2 Main production sites and transportation of creatine in the body
Main production sites of endogenous creatine are found in the liver (Walker, 
1979), pancreas and kidney (Horn et al., 1998). Endogenous creatine is then 
released into the bloodstream to be taken up by various organs (heart, brain) and 
skeletal muscle. This uptake of creatine is mediated by a specific creatine 
transporter protein (Horn et al.. 1998). Horn et al. (1998) found that when adult
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rats are supplemented with exogenous creatine, the creatine concentration in the 
liver and kidney is increased, but no significant increases were found in the 
skeletal muscle or brain tissue.
Although creatine is produced endogenously in the body, it needs to be 
transported to the areas with a high creatine kinase content. Creatine then needs 
to be transported through biological membranes (i.e. cell and mitochondrial 
membranes). Wyss and Kadurrah-Daouk (2000) stated that creatine uptake into 
skeletal muscle, kidney, brain or heart (creatine kinase-containing organs) is 
mediated by a “specific, saturable Na+ -and Cr -dependent creatine transporter”. 
These researchers also state that this transporter might be influenced by 
hormonal and/or dietary factors.
It has also been shown that an increase in creatine concentration tends to cause 
an increase in insulin-like growth factor (IGF) (Odoom et at., 1996; Persky and 
Brazeau, 2001). Odoom et at. (1996) have shown that IGF has a stimulating 
effect on the sodium-potassium pump. The sodium-potassium pump transports 
creatine, against the concentration gradient, through the biological membranes 
and into the cells (Steenge et at., 1998; Wyss and Kadurrah-Daouk, 2000; 
Persky and Brazeau, 2001).
Creatine is stored in two forms in the body, namely free creatine (FCr) (40%) and 
phosphorylated creatine, better known as phosphocreatine (PCr) (60%). Total
6
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body creatine (both FCr and PCr) yields about 120 grams of creatine in a 70kg 
individual. Ninety-five percent of creatine is stored in skeletal muscle (Williams et 
al, 1999; Persky and Brazeau, 2001).
2.3 Placental crossing of creatine
As previously mentioned, the liver, pancreas and kidney are primary sites of 
production of creatine (Horn et al., 1998). It was, however, recently discovered 
that high levels of AGAT were also present in the rat deciduoma (Wyss and 
Kadurrah-Daouk, 2000). In addition Sandell et al. (2003) observed that GAMT 
expression was highest in mouse embryonic and extraembryonic tissue from 
conceptuses between embryonic day E7.5 and E9.5. Sandell et al. (2003) 
compiled an expression profile of E10.5-E18.5 embryos (just embryonic tissue). 
GAMT expression was found to be very low in these tissues at E10.5 while the 
expression gradually increased in the embryo until day 17.5, at which stage the 
embryonic and placental GAMT expression became uniform (Sandell et al., 
2003).
The placenta is thus a production site of creatine (AGAT and GAMT 
expression)(Sandell et al., 2003). In addition, creatine is said to readily cross the 
placenta into the foetal blood system (University of Michigan, Laboratory notes, 
unpublished data).
7
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2.4 Metabolic functions
Creatine is well known as a supplement that increases muscle mass (see section 
3), power, and enhances sport performance (Mujika and Padilla, 1997; Wyss and 
Kadurrah-Daouk, 2000; Persky and Brazeau, 2001; Brudnak, 2004). These 
effects may occur through creatine’s involvement in several metabolic functions. 
The most common metabolic functions in which creatine is involved, are 
buffering, stabilization of the mitochondrial membranes, axonal elongation, 
insulin sensitivity, GLUT4 upregulation, as well as in the production of energy. 
During the production of energy, adenosinediphosphate (ADP) and PCr form 
adenosinetriphosphate (ATP) and Cr. Energy is set free as ATP loses an 
inorganic phosphate (Pi) through the enzyme ATPase, thus forming ADP and Pi 
(see section 1 for mechanism).
ADP + PCr -> ATP + Cr -— ATPase---------> ADP +Pi
Due to the degradation of PCr to Pi and creatine, the ATP pool has an effective 
turnover of several dozen times when ATP breaks up into ADP +Pi, releasing 
massive amounts of energy during high-intensity exercise (Campbell, 1995).
Daily degradation of creatine to creatinine is about 1.6% (Stockier, 1997). This is 
a simple, irreversible reaction that occurs spontaneously inside the muscle
8
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(Clark, 1997; Crim et al., 1975, 1976). Creatinine enters the bloodstream and is 
filtered out through the kidneys and excreted in the urine (Greenhaff, 1997).
3. EFFECTS OF CREATINE SUPPLEMENTATION ON BODY MASS AND 
COMPOSITION
An increase in body mass is one of the effects of creatine supplementation 
(Guzik et al., 2000; Wyss and Kadurrah-Daouk, 2000). Creatine is an osmotically 
active substance (Williams et al, 1999) such that an increase in the creatine 
concentration of the cell will result in an increase of water in the cell (Volek et al., 
1997a; 1997b; Ziegenfuss et al., 1998; Wyss and Kadurrah-Daouk, 2000; 
Brudnak, 2004). This could explain the rapid increase in body weight following 
exogenous creatine supplementation. It has also been shown that an increase in 
intracellular water may stimulate protein synthesis or decrease protein 
degradation (Clark, 1997; Ingwall, 1996; Mujika and Padilla, 1997; Volek and 
Kraemer, 1996; Volek et al., 1997a; 1997b).
Normal values for creatine in muscle are 115 -  120 mmol/kg dry muscle 
(determined by the snap-freezing technique) (Harris et al., 1992). This 
concentration in muscle can increase to 160-mmol/kg dry muscle (Hochachaka 
and Mossey, 1998), which is the muscle threshold for creatine following 
exogenous creatine intake.
9
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The human population can be divided into three groups: a sedentary group, a 
physically active group and a highly trained group of athletes. In experiments 
carried out to determine the effect of short-term creatine supplementation, 
subjects were chosen from these three population groups as well as matched 
control groups. The sedentary subjects (0.35g creatine/kg body weight for 5 
days) showed a significant increase in body mass following exogenous creatine 
supplementation although they were not physically active (Ziegenfuss et a/., 
1998). The physically active group (25g/day for 6 days, (0.35g creatine/kg 
bodyweight)) showed significant increases in body mass, while the control group 
had a decrease of body mass due to the rigorous training (Balsom et al., 1993). 
The highly trained athletes also showed a significant increase in body mass. This 
gain in body mass was achieved with relatively small doses of creatine (20g/day 
for 5 days, 0.285g creatine/kg bodyweight) (Mujika et al., 1996)
4. REPORTED SIDE EFFECTS
Anecdotal reports indicate that creatine may cause gastro-intestinal distress 
(stomach upset, diarrhoea), muscle cramping and muscle injury. However, 
Williams et al. (1999) reported that there is no scientific evidence to substantiate 
these findings. In a previous study carried out by Badenhorst and Vorster (2000, 
unpublished data), creatine caused growth retardation in the developing chick 
embryo. Abnormalities included degeneration of the retina and sclera and
I0
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massive subcutaneous haemorrhaging. The ventral thoracic wall failed to close, 
leaving the heart exposed.
5. MEDICAL USES OF CREATINE
Although creatine is mainly used for weight gain and muscle building, research 
has shown that creatine can be used as a supplement to aid in the recovery of 
certain disorders. Creatine is also said to have an effect on degenerative muscle 
diseases and loss of neural function during the aging process (Williams et al, 
1999, Wyss and Kadurrah-Daouk, 2000).
5.1 Heart disease
Creatine has the ability to influence cardiac and neural functions. Research has 
been carried out to determine the effect of creatine on myocardial metabolism 
and degenerative diseases of the myocardium i.e. heart failure, ischemia and 
ventricular arrhythmias (Conway et al., 1996; Saks et al., 1996). Improved 
myocardial metabolism and the reduction of incidence of ventricular fibrillation in 
ischemic heart patients were found when PCr was intravenously administered 
(Constantin-Teodosiu et al., 1995; Conway et al., 1996; Andrews et al., 1998). 
The explanation for this was that the viability of the ischemic cell membrane is 
improved by the administration of exogenous creatine, thus minimizing injury to 
the cell during ischemia (Saks et al., 1996). All the abovementioned researchers
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concluded that intravenous PCr injections offer an effective cardioprotective 
function in patients that suffer from ischemic heart disease.
5.2 Tumour growth inhibition
Miller et al. (1993) evaluated the effects of creatine and cyclocreatine on the 
growth rates of rat mammary tumours and sarcoma in male rats. In addition, 
Miller et al. (1993) evaluated the growth of tumour cells, which were injected 
subcutaneously in mice. They found that administration of cyclocreatine to the 
affected animals delayed the appearance and growth of the tumour cell 
populations subcutaneously in rats and mice, but concluded that additional 
research was necessary to explore its potential medical benefit.
Wyss and Kadurrah-Daouk (2000) found that cyclocreatine acts as a tumour 
repressor or anti-tumour agent (Persky and Brazeau, 2001). Cell lines with high 
creatine kinase concentrations were not inhibited following exposure to 
cyclocreatine (Wyss and Kadurrah-Daouk, 2000). It was speculated that in 
tumour cells, cyclocreatine did not cause excessive water influx into the cells; 
thus cyclocreatine acts as an efficient anti-tumour agent (Wyss and Kadurrah- 
Daouk, 2000). Wyss and Kadurrah-Daouk (2000) maintain that creatine can 
induce tumour growth; whereas creatine analogs can inhibit tumour growth.
I2
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5.3 Creatine synthesis deficiencies
Due to an inborn error in GAMT production (Wyss and Kadurrah-Daouk, 2000), 
some babies are unable to synthesize creatine endogenously (Arias-Mendoza et 
al., 1998). These creatine-deficient babies displayed significantly decreased 
motor and neural functions (Wyss and Kadurrah-Daouk, 2000), which in turn 
caused abnormal mental, neuromuscular and physical maturation (Stockier et al., 
1997). When oral creatine supplementation (for up to 25 month’s duration) was 
given to these babies, they experienced normal physiological and mental 
development (Stockier et al., 1994; 1996a; 1996b; Stockier and Hanefeld, 1997).
6. AIM OF STUDY
It has been shown that many female athletes take exogenous creatine 
supplementation to enhance their performance (Wyss and Kadurrah-Daouk, 
2000; Persky and Brazeau, 2001). If the athlete was to become pregnant, and 
due to the ability of creatine to cross the placenta (University of Michigan, 
laboratory notes, unpublished data), as well as the placenta being a site for 
endogenous creatine synthesis, creatine may have an influence on the 
developing embryo/foetus. In a previous study carried out by Badenhorst and 
Vorster (2000, unpublished data), it was observed that creatine delayed 
development and growth in chick embryos. Creatine also induced abnormalities 
such as ectopia cordis and subcutaneous haemorrhaging.
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The aim of the present study utilizing a mammalian model in order to mimic the 
human condition, was thus:
1. To investigate whether exogenous creatine (creatine supplementation) 
has an effect on the development of the rat embryo and/or foetus;
2. To determine whether abnormalities occur following either isolated 
intake or prolonged exposure to creatine;
3. To determine if abnormalities (should they occur) are dose-dependant.
7. MATERIAL AND METHODS
7.1 Rationale for the use of Sprague-Dawley rats
The rat has several advantages for embryological study, especially when a 
teratogen is involved. Some of the advantages of working with rats are that they 
are relatively disease resistant, have a short reproductive cycle (with well 
documented staging of the developing foetus), and the foetuses are large 
enough to work with conveniently. Sprague-Dawley rats were selected for this 
particular study, as they have a low spontaneous rate of malformation. In 
addition, Sprague-Dawley rats are freely available.
I 4
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7.2 Rat breeding and maintenance
Four fertile male and forty-four female Sprague-Dawley rats were used for this 
study. The rats were obtained from the Central Animal Unit of the University of 
the Witwatersrand, (Animal ethics clearance number 2003/48/3)(Appendix A). 
Female rats were housed (four rats per cage) in the Central Animal Unit, with a 
controlled temperature of 21 ± 1°C and 50 -  60 % relative humidity. A 12-hour 
light: 12-hour dark cycle was maintained. Their diet consisted of water and rat 
cubes ad libitum.
7.3 Determination of pregnancy
Vaginal smears were carried out daily to determine the stage of the oestrus cycle 
of each animal. Swabs for vaginal smears were made of toothpicks that were 
rolled in cotton wool. The swabs were smaller than ear bud swabs and thus the 
risk of injury or discomfort to the animal was greatly decreased.
After the vaginal smear was taken, the sample was smeared on to a glass slide. 
The smear was then fixed with alcohol and immersed in Shorr’s stain (Drury and 
Wallington, 1980)(Appendix B).
The smears were immersed in the staining solution for one minute and were then 
washed in 70% ethanol. The smears were dehydrated through a graded series of
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alcohols (95%, 95% and 100%) and placed in Xylene. Coverslips were mounted 
with Entellan.
The smears were viewed with a Zeiss light microscope. The smear was 
classified, according to Kent’s staging (1945), as being either in the oestrus, 
metoestrus, early dioestrus, mid-dioestrus, late dioestrus or in the proestrus part 
of the oestrus cycle.
Females were allowed to progress through three normal 4-day oestrus cycles 
and were then classified as ready for mating. On the day before oestrus of their 
4th cycle, a female was placed in a breeding cage (drop tray) with a fertile male. 
The animals were caged overnight. The presence of a vaginal plug the following 
morning indicated that copulation had taken place. A vaginal smear was made to 
ascertain whether any sperm were present. The day the vaginal plug was found, 
as well as positive evidence of sperm in the vagina when a vaginal smear was 
taken, was recorded as day 0 of pregnancy.
7.5 Experimental groups
Forty-two dams were divided into six groups.
1 Control groups: A (n=7) and B (n=7). These animals were given an 
intraperitoneal injection of a solution of 0.9% sterile NaCI. This solution
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was also the vehicle that was used to deliver the creatine to the 
experimental groups. (For times of injections, see section 7.4.1).
2 Experimental groups: A1, A2, B1 and B2
a) A1 (n=7) and B1 (n=8): Animals in these groups were injected 
intraperitoneally with 53.5 mg creatine/250 g body weight made up 
in a 0.9% sterile NaCI saline solution (also referred to as 15g/day or 
low dose group (see sections 7.4 and 7.5.1 for rationale)).
b) A2 (n=7) and B2 (n=8): Animals in these groups were injected 
intraperitoneally with a solution 107 mg creatine/250 g body weight 
made up in a 0.9% sterile NaCI saline solution (also referred to as 
30g/day or high dose group (see section 7.4 and 7.5.1 for 
rationale)).
Groups will now be referred to as control group A or B and experimental groups
A1, A2, B1 and B2.
7.5. Dosage of creatine
Dosages were calculated from the amount of creatine consumed by a normal 
physically active person (70kg male)(Feldman, 1999). The dosage was then 
recalculated to the amount that an adult female rat of approximately 250 grams 
would consume. Women athletes usually take a loading dose or a maintenance
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dose of creatine for at least a week. Dosages were calculated to a normal 
maintenance dose (15g/day) or a loading dose (30g/day)(Feldman, 1999).
One millilitre of the creatine-saline solution was injected intraperitoneally into the 
experimental and control groups. Usually, when exogenous creatine is ingested, 
the creatine is made up in 500ml of water per 70 kg individual. Recalculation to 
rat weight estimated that an amount of 1,7ml of the solution would be needed. 
After careful deliberation with the veterinarian in the Central Animal Unit (Dr. L. 
Sinclair), it was decided that approximately 2 ml of the solution might cause 
intestinal distress and intraperitoneal discomfort to the animal, thus jeopardizing 
the experiment. A volume of 1 ml of the creatine-saline solution was thus decided 
on. This would deliver sufficient creatine for the purpose of the experiment.
7.5.1 Rationale for the dosages used
Creatine is fully soluble in saline. The 53.5mg/250g body weight dose was 
chosen as it is equivalent to a maintenance dose of 15g/70kg in the daily training 
of athletes (Wyss and Kadurrah-Daouk, 2000, Persky and Brazeau, 2001; 
Brudnak, 2004). The 107mg/250g body weight is equivalent to a loading dose 
used by athletes when they wish to boost their creatine levels (30g/70kg daily) 
(Wyss and Kadurrah-Daouk, 2000, Persky and Brazeau, 2001; Brudnak, 2004). 
Control group A, as well as experimental groups A1 and A2, were injected 
consecutively from day 7 to 13 of embryonic development (for rationale of time
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periods, see section 7.5.3). Control group B, as well as experimental groups B1 
and B2, received two injections: the first on day 9, and the following on day 11 of 
embryonic development. Days 9 and 11 were chosen due to the critical stages of 
organogenesis, which occur at this time (see section 7.5.3).
7.5.2 Route of administration
Usually creatine is ingested orally, but in the current experiment, an 
intraperitoneal injection of the solution was used. The rationale for using an 
intraperitoneal route rather than an oral route was: 1) it would be difficult to 
determine the amount of creatine that the rat ingested if the creatine was mixed 
with the food and 2) intraperitoneal injections were favoured as the solution 
would be absorbed into the bloodstream relatively fast. The intact molecule of 
creatine passes through the intestinal wall when ingested orally and thence into 
the portal hepatic system that would take it directly to the liver (Wu and 
Meininger, 2000; Wyss and Kadurrah-Daouk, 2000). With intraperitoneal 
injections, the injected creatine would reach the liver through the hepatic portal 
vein.
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7.5.3 Organogenesis on selected days of rat embryo/foetus development 
with particular reference to specific organs and structures
Days 7-13 (group A) and days 9 and 11 (group B) of embryonic development 
were chosen due to specific development of critical organs at this time (Baker et 
al., 1980). See Appendix D for events of organogenesis during these stages of 
development.
7.6 Sacrificing of animals
All dams were killed on day 20 of embryonic development. As birth occurs on day 
21, and in order to avoid the killing of individual foetuses, day 20 was selected for 
termination of pregnancy. All the major organs will have reached completion by 
this time. An intraperitoneal injection of Sodium Pentobarbitone (Eutha-nase) 
(1ml/350gram rat) was injected into the dams.
7.7 Collection and processing of foetuses
A mid-abdominal section was made and the uterine horns were exposed and 
excised. The number of foetuses present was counted, as well as the number of 
resorbed foetuses. The foetuses were then dissected free of the uterine horns 
and of their placentas. Measurements were carried out to determine if prolonged 
doses of creatine affected overall growth of the foetuses. The weight of each
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foetus was estimated to the nearest 0.05g using a Sartorius scale. Crown-rump 
(length) measurements of each foetus were taken. A vernier calliper (calibrated 
to read 0.05 of 1 mm) was used for this measurement. All foetuses were 
examined with a stereomicroscope to see whether any obvious external 
abnormalities were present.
7.7.1 Preparation of foetuses for light microscopy
Foetuses were placed in Allen’s fixative (Gray, 1953)(See Appendix B for 
method) for at least 72 hours. Fixed foetuses were immersed in a decalcification 
solution (Bancroft and Gamble, 1998). The decalcification solution consisted of a 
90% formic acid-formalin solution (Bancroft and Gamble, 1998) into which 
foetuses were placed for three days. Foetuses were then put into a fresh solution 
of 90% formic acid-formalin at the beginning of the fourth day, for a further two 
hours. The fresh solution will remove any calcium that is still present in the bone 
and cartilage. An “endpoint” test was carried out to determine whether all the 
calcium had been removed (Bancroft and Gamble, 1998). This was done by 
slowly adding concentrated ammonia to 5ml of the 90% formic acid-formalin 
solution, slowly until a pH of 7 was reached (determined by using litmus paper). If 
there was no cloudiness in the solution, this meant that all the calcium had been 
removed from the foetuses. The foetuses were then ready for processing for light 
microscopy, which was carried out in a Sanford tissue-processing machine. The 
processing machine was programmed to take the foetuses through a graded
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series of alcohol starting with 75% alcohol (2hrs), 90% alcohol three times (3hrs 
each time) and then three changes of absolute alcohol (3hrs each change). The 
foetuses were immersed in chloroform twice (4hrs each change) and lastly 
placed into warm paraffin wax twice (6hrs each). After processing, the foetuses 
were embedded in fresh paraffin wax.
Foetuses were sectioned on a sledge microtome at five pm. Sections were then 
placed on clear glass slides and dried in an oven for two hours at 90°C. Prior to 
staining, sections were dewaxed in xylene for 5 minutes. The sections were 
dehydrated through a graded series of alcohols and then washed in running 
water (10 min) to remove the picric acid residue (yellow pigment) in the sections. 
The sections were then placed in haematoxylin (5 min), washed in water (30 
seconds), differentiated in acid alcohol (3 dips) and again rinsed in water. 
Sections were immersed in eosin (1min), rinsed in running water, and taken 
through a graded series of alcohols to dehydrate. The sections were then placed 
in xylene. Entellan was used to mount the coverslips on the sections. Sections 
were viewed using a Zeiss light microscope to determine any histological 
abnormalities.
7.7.2 Skeletal staining using Alizarin red S and Alcian Blue
Foetuses from both the control and experimental groups were used (n=44). An 
Alizarin red S and Alcian Blue technique (Menegola et al., 2001 )(Appendix B)
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was used to demonstrate development of cartilage and bone in the foetus. After 
the foetuses had been weighed and their length taken, they were placed into a 
solution of 4% NaCI overnight. The following day the foetuses were taken out of 
the solution, eviscerated, and skinned. They were then immersed in an acidic 
staining solution (ph 2.7)(Alcian blue (Sigma Aldrich) and Alizarin red S (Sigma 
Aldrich)) for 24 hours, followed by 96% ethanol to dehydrate. Foetuses were then 
placed in a basic staining solution of 0.7% KOH and Alizarin red S for a further 
30 hours. The basic staining solution caused maceration of the soft tissues. A 
clearing solution, which consisted of 70% ethanol, glycerine and benzyl alcohol 
was used. The foetuses were then preserved in a 70% alcohol: glycerine 
solution.
7.7.3 Immunocytochemistry (ICC)
One section of each pancreas was stained with haematoxylin and eosin for 
routine histological examination.
This section underwent dewaxing in xylene. Normal haematoxylin and eosin 
histological staining technique was followed (see section 7.8.1). The section from 
each group was then examined with a light microscope to confirm that the tissue 
was present. After confirmation of pancreatic tissue, the other sections then 
underwent immunocytochemistry. Immunocytochemical localization for insulin
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and glucagon was carried out on pancreatic tissue from randomly selected 
foetuses of each control and experimental group (n=4/group).
Sections of pancreatic tissue were cut (5pm) and placed on clean glass slides 
and allowed to dry for two hours at 90°C in an oven. An indirect immunoenzyme 
procedure (see Appendix B) was used to detect whether u - and p-cells were 
present. Insulin antiserum (Euro Diagnostech)(1:800) was raised to detect any 
immunoreactivity against natural guinea-pig insulin, while glucagon antiserum 
was raised against natural rabbit glucagon (Euro Diagnostech)(1:1000) to test for 
immunoreactivity against glucagon. Antisera (30pl/section) were applied to 12 
randomly selected sections of each pancreas respectively.
Sections for immunolocalization were dewaxed in xylene and hydrated through a 
graded series of alcohols. All the sections were then immersed in distilled water. 
After rinsing the sections at least twice in distilled water, the sections were then 
placed in Tris/saline (see Appendix B). The sections were submerged in a 3% 
hydrogen peroxide/distilled water solution and left to stand for 10 minutes. The 
sections were washed again for 5 minutes in Tris/saline. Non-specific localization 
was then blocked by adding 10% swine serum (see Appendix B) on to the 
sections. The sections were then left in a damp chamber for 10 minutes (room 
temperature). Sections were drained of swine serum and were carefully wiped 
around the section to remove all the remaining serum. The sections were then
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incubated with 30 pi primary antibody at a concentration of 1: 800 for insulin 
(Euro Diagnostech) and 1:1000 for glucagon (Euro Diagnostech) at 4°C.
The following day the sections were drained and washed for 15 minutes in 1% 
horse serum (3x5min, each time renewing the solution). Sections were drained of 
the horse serum and placed in the damp chamber. The secondary antibody was 
then pipetted onto the section. Anti-guinea pig secondary antibody (1:20)(DAKO) 
was used for insulin, while anti-rabbit secondary antibody (1:20)(DAKO) was 
used for those sections that were immunolocalized with glucagon. The sections 
were then left in the damp chamber for 1 hour (room temperature). Sections were 
drained again and washed for 15 minutes (3x5min) in a Tris/saline solution, 
renewing the solution every 5 minutes. Sections were then incubated with a 
diaminobenzidine (DAB) solution (see Appendix B) and timed individually for 5 
minutes in order to avoid background overstaining. Sections were then placed in 
distilled water and immersed in gently running tap water for a further 5 minutes. 
Sections were then dehydrated through a graded series of alcohols and cleared 
in xylene. Coverslips were mounted with Entellan.
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7.7.3.1 Immunocytochemical controls
Absorption controls were established by substituting the primary antisera with the 
primary antiserum which had been pre-absorbed with its own antigen (natural 
guinea pig insulin at 20(.ig/ml, Euro Diagnostech; natural rabbit glucagon at 
40pg/ml, Euro Diagnostech) overnight at 4°C. Sections adjacent to sections 
showing immunolocalization for insulin and glucagon respectively, were then 
incubated with the antibody-antigen complex for one hour at room temperature.
Sections adjacent to the sections that showed immunolocalization of insulin and 
glucagon were used as negative immunocytochemical controls. In these 
sections, either the primary antiserum or secondary antiserum was substituted 
with Tris/Saline ora nonimmune serum of the relevant species.
Sections of pancreas from an adult female rat were used as positive controls in 
this study. After the immunocytochemical procedure, definite a- and (1- cell 
immunolocalization could be observed in the pancreatic sections.
7.8 Statistical methodology (see Appendix E for raw data, calculations and 
graphs)
In order to determine whether the data was normally distributed, the weight and 
length of foetuses were sorted from the smallest value to the biggest value in
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each group and the frequency determined. The interval in the weight category 
was equal to one (one gram interval), while an interval of five was used with the 
calculation of the length frequency. From the frequency table, an observed value 
could be determined, while an expected value was calculated using the formula 
y=(N x i/sdV2n)e'(xmx)2/2sd2 (personal communication Prof J.C. Allan). The 
observed and expected values were then used to draw graphs and to determine 
whether there was a normal distribution in the data presented. y2-tests were also 
carried out to determine if there were significant differences between the 
observed and expected values. These tests showed that there was no significant 
difference in values in the length group (see section 8.6.2). It was thus decided 
on the advice of a statistician (Prof. J.C. Allan) to use Students “t”-test to 
determine whether there were significant differences between the experimental 
groups. As the chi-square test showed a significant difference in the normal 
distribution for weight between the observed and expected values, it was decided 
to make use of a non-parametric test. The Mann-Whitney test for large samples 
of uncorrelated data was used to determine if there were any significant 
differences between the experimental and control groups in relation to weight.
7.9 Photography
Photos of abnormal macroscopic development were taken with a digital camera. 
Unfortunately a scale was not included in the photographs.
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8. RESULTS
8.1 General
Three hundred and forty foetuses were collected from 40 pregnancies. One 
hundred and sixteen absorption sites were found. Four out of forty dams were 
pseudopregnant. Pseudopregnancy, as defined by Salamonsen et al. (1996), is 
when an animal exhibits all the necessary signs of pregnancy (vaginal plug, 
weight increase), but when killed, has no foetuses or absorption sites present.
8.2 Surviving foetuses vs. absorbed foetuses
Three hundred and forty foetuses were collected in total. The percentage of 
surviving foetuses vs. absorbed foetuses across all the groups is 25.4%. The 
highest number of absorption sites was found in the B2 experimental group (high 
dose, injected days 9 and 11). More absorption sites were found in the B-groups 
(experimental) when compared to the A-groups (experimental). Figure 2 depicts 
the survival: absorption ratio for the different groups.
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□ Surviving 
foetuses
□  Absorbed 
foetuses
Figure 2. Number of surviving foetuses vs. absorbed foetuses in control and experimental groups.
In the A-group (CA, A1 and A2)(injected for 7 days consecutively) the respective 
percentages were 21% (13/63) absorbed foetuses (control, saline), 3% (3/92) 
absorbed foetuses (A1, low dose) and 14% (11/78) of foetuses absorbed (A2, 
high dose). In the B-groups (CB, B1 and B2)(injected on days 9 and 11 of 
embryonic development), there was a marked increase in the number of 
absorbed sites. Control group B showed a 42% (31/74)) absorption percentage, 
while the two experimental groups (B1 (low dose) and B2 (high dose)) each 
showed a 28% (24/85) and 53% (34/64) absorption rate respectively.
8.3 Subcutaneous haemorrhaging and underdevelopment of foetuses
Foetuses with severe subcutaneous haemorrhaging (figure 3) were observed, 
particularly in the groups that were treated with creatine. The number of foetuses 
observed in each group which suffered from subcutaneous haemorrhaging was 
2/50 in control group A (4%), 1/89 in A1 (1.1%), 2/67 in A2 (3%), 1/43 in control 
group B (2%), 4/61 in B1 (6.5%) and 2/30 in group B2 (6.6%) (figure 4). Of the
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groups that were treated with creatine, the B1 experimental group (low dose, 
days 9 and 11 injected) had the most foetuses that suffered from subcutaneous 
haemorrhaging.
groups.
In one animal in the B1 experimental group, the whole body of the foetus was 
covered with a subcutaneous haematoma which stretched from the pelvic area to 
the cranial region. In severe cases, the haematoma covered the whole of the 
cranium as well (figure 5).
8.4 Macroscopic abnormalities
8.4.1 Control group A (saline, consecutive injections)
This group contained fifty foetuses. Two foetuses from this group were found to 
suffer from subcutaneous haemorrhaging. In addition, 14 underdeveloped 
(underdeveloped = behind normal developmental stage, weighed significantly
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less than group mean and was of a shorter length than the mean length of the 
group) were noted. The most severely affected foetus displayed crystal-like 
structures in the abdominal area (figure 6).
8.4.2 Experimental group A1 (low dose, continuous injections)
This group had one foetus that showed extensive subcutaneous haemorrhaging. 
All the foetuses in this group suffered from extensive haematomas in the 
temporal region. Figure 7 depicts abnormal development of the temporal artery in 
one foetus. Normally the temporal artery would be anterior to the ear and runs in 
a vertical direction on the desmocranium. In the foetus in figure 7, the artery runs 
posterior to the ear and in a more horizontal direction on the desmocranium. The 
abnormal development of this artery may be related to a temporal haematoma.
This experimental group also had a higher incidence of underdeveloped foetuses 
when compared to the other experimental groups and control group B. Group B1 
(low dose, days 9 and 11 injected) and control group A (saline, continuous 
injections) had the most underdeveloped foetuses.
8.4.3 Experimental group A2 (high dose, continuous injections)
Although this group showed the highest mean weight (4.797 grams) of all the 
experimental groups (groups A1, A2, B1 and B2)(see Appendix C), it was found 
that this group also had the most severe subcutaneous haemorrhaging (figure 8) 
which tended to spread over the whole of the body of the foetus.
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Temporal bleeding in this group was also found to be the most severe of all the 
experimental groups (figure 9).
Foetuses from this experimental group, which suffered from subcutaneous 
haemorrhaging, also had a high incidence of crystal-like structures forming on 
the abdominal surface. When these foetuses were eviscerated, it was observed 
that the crystal-like structures were also present in the abdominal cavity (figures 
6 and 10). Crystal-like structures were also found in the temporal region of 
certain foetuses in this particular group.
8.4.4 Control group B (saline, days 9 and 11 injected)
The foetuses in this group did not demonstrate extensive subcutaneous 
haemorrhaging. Out of 43 foetuses, haemorrhaging was observed in five 
foetuses (11.6%). Haemorrhaging was localized to the abdominal area and 
sometimes extended into the thorax. No temporal or extensive subcutaneous 
haemorrhaging was observed in the animals of control group B [(compare figure 
6; (control foetus with mild abdominal haemorrhaging) to figure 5 (experimental 
foetus with severe haemorrhaging)].
8.4.5 Experimental group B1 (low dose, days 9 and 11 injected)
This group had 4/61 foetuses displaying extensive subcutaneous bleeding 
(figures 11 and 12) as well as subcutaneous abdominal haemorrhaging. Two 
foetuses displayed signs of extensive temporal haemorrhaging (figure 12).
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This experimental group had the second most underdeveloped foetuses (figure 
13)( 19.7%) of all the control and experimental groups; besides control group A 
(saline, consecutive injections). It was observed that these underdeveloped 
embryos were at least 3-4 days behind average development with regard to 
length and weight data compared to control groups at the same stage. Crystal­
like structures were also found in one foetus that suffered from extensive 
subcutaneous haemorrhaging.
8.4.6 Experimental group B2 (high dose, days 9 and 11 injected)
Experimental group B2 had two foetuses (2/30; 6.7%), which suffered from 
extensive subcutaneous haemorrhaging and subcutaneous haemorrhaging in the 
abdominal area. Temporal bleeding was observed in one foetus. One foetus from 
the total group (1/340) did not develop a superficial temporal artery (figure 14).
8.5 Statistical analysis
8.5.1 Weight and length averages
Means of weight and length from the foetuses in the different experimental and 
control groups were calculated. It was found that control group B had the highest 
overall weight (figure 15), while experimental group A2 had the highest overall 
length of all the groups (figure 16).
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Figure 16. Average length of foetuses in experimental groups.
Experimental group B1 had both the smallest mean weight and length, while 
control group A and experimental group B2 had almost similar values in both the 
weight and length charts (figures 15 and 16).
8.5.2 Length statistics
Groups were compared (see section 7.9 Statistical methodology) using Student’s 
“t”-test. An a-level of 0.05 (P<0.05) was used as an indicator to determine
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whether there would be a probable chance of significance between group A and 
group B. Control groups were compared with their respective experimental 
groups. When compared, it was found that CA-A1 groups were not significantly 
different (P>0.05). Groups CA-B1, CA-B2, A1-B2, A2-CB and B1-B2 were also 
not significantly different. Groups CA-A2, CA-CB and B2-B1 had a P<0.01 value, 
while the groups A1-A2, A1-CB, A1-B1, A2-B1, A2-B2, CB-B1 and CB-B2 all had 
a significant P value either equal to 0.001 or less than 0.001. This would mean 
that there is an almost certain probability that there is a significant difference 
between the groups just described. (Refer to table 1).
P>0.05 P<0.01 P<0.001
CA-A1 CA-A2 A1-A2
CA-B1 CA-CB A1-CB
CA-B2 B2-B1 A1-B1
A1-B2 A2-B1
A2-CB A2-B2
B1-B2 CB-B1
CB-B2
Table 1. Groups in each column that were not statistically significant or were statistically 
significantly different pertaining to length
8.5.3 Weight statistics
The foetuses from the control and experimental groups were compared with 
regard to their weight (refer to table 2). Groups which had a P<0.05 were CA-A1, 
CA-CB, CA-B1, CA-B2, A1-B1, A1-B2, A2-CB and B1-B2 (refer to table 2).
CA-A2 and CB-B2 were between 0.05>P>0.01. The groups A1-CB, A2-B2 and 
CB-B1 all had a p-value that was smaller than 0.01, but bigger than 0.001
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(0.01>P>0.001). Groups A1-A2 and A2-B1 had P-values smaller than 0.001 
(P<0.001).
P>0.05 P<0.05 P<0.01 P<0.001
CA-A1
CA-CB
CA-B1
CA-B2
A1-B1
A1-B2
A2-CB
B1-B2
CA-A2
CB-B2
A1-CB
A2-B2
CB-B1
A1-A2
A2-B1
Table 2. Groups in each column that were not statistically significant or were statistically 
significant pertaining to weight.
8.6 HISTOLOGICAL STUDY OF PARTICULAR ORGANS
A histological study was undertaken on the kidney, skeletal muscle, liver and 
pancreas. These organs are active in creatine synthesis, creatine transport or 
utilization of creatine in the adult. Any effects that may occur in these 
organs/tissues in the developing foetus would be due to the administration of 
creatine.
8.6.1 Kidney
When kidney sections from the different groups were compared at the light 
microscopic level, it was found that there were no differences in tissue or cellular 
structure between the control and experimental groups, whether they were 
injected consecutively or only on the two selected days. A cortex and medulla
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could be clearly distinguished. The nephrons and collecting duct system 
appeared normal (figure 17).
8.6.2 Skeletal muscle
Skeletal muscle had undergone normal development in the foetuses of control 
groups A (figure 18) and B (figure 19) for that particular stage of development. 
Skeletal muscle from experimental group A1 (low dose, continuous injections) 
showed similar features to that of the control animals. The striation pattern 
(experimental group A1, figure 20) was very clear and at the same stage of 
development as that of the control group. However, when the muscle of 
experimental animals in group A2 (high dose, continuous injections) was 
compared with the muscle of control animals and of experimental animals (group 
A1), it was observed that the skeletal muscle fibres appeared to be more densely 
“packed” than in both the control group and experimental group A1. It appeared 
that there were more fibres per section area in animals from experimental group 
A2 (quantitation not carried out). There also appeared to be more striations in the 
muscle fibres from experimental group A2 than from group A1 or the control 
group (figure 21). Muscle fibres from the foetuses of the B1 (low dose, day 9 and 
11 injected) (figure 22) and B2 (high dose, day 9 and 11 injected)(figure 23) 
experimental groups appeared to be immature when compared to control groups 
A and B. Banded striation patterns (experimental group B1) were visible, but 
were not as densely compacted compared to the A-groups (experimental). The 
muscle fibres from foetuses form both the B1 and B2 groups (experimental) also
37
The effect of creatine on the developing rat foetus
appeared disorganized. Striations in muscle from the foetuses of the B2 
experimental group were faint to almost non-existent, when compared to control 
groups A and B and experimental groups A1, A2 and B1.
8.6.3 Pancreas
Absorption (figure 24), negative (figure 25) and positive (figure 26) 
immunocytochemical control gave satisfactory results indicating that the antisera 
used were specific.
In control groups A and B, large islets containing both insulin-secreting cells 
(figure 27) and glucagon-secreting cells (figure 28) were observed. These had 
the typical mammalian pattern of a mantle of a-cells and a core of p-cells. In 
experimental group A1 (low dose, continuous injections), the a- and (5-cells were 
not as intense as in the a- and (5-cells in the pancreata of the A and B control 
groups.
Islets [containing both a- (figure 29) and p-cells (figure 30)] although not 
quantitated, appeared to be more numerous in pancreata of animals from group 
A2 (experimental, figure 31), compared to the other experimental and control 
groups.
In the B1 experimental group, a- and p-cells (figures 32 and 33) displayed 
intense localization. The B2 experimental group also displayed a- and p-cell
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immunolocalization (figures 34 and 35), but this was not as intense as that in 
control groups A and B and the other experimental groups. Although not 
quantitated, the B1 group appeared to have the most numerous p-cell population.
8.6.4 Liver
An abundance of liver cord cells (precursors to normal hepatocytes) were 
observed in control groups A (figure 36) and B. Numerous precursor blood cells 
were also observed. Sinusoids in the control groups appeared to be relatively 
wide.
In experimental group A1 (low dose, consecutive injections), there was a general 
decrease in the number of liver cord cells and the sinusoids were distended 
(figure 37) compared to the tissues of the control group A. Experimental group 
A2 (high dose, consecutive injections) also displayed relatively wide sinusoids 
(figure 38) compared to control groups A and B. Although not quantitated, an 
increase in liver cord cells was observed in sections of liver from experimental 
group A2 when compared to liver sections from experimental group A1.
Sinusoids in experimental group B1 (low dose, days 9 and 11 injected) were 
narrow and filled with erythrocytes (figure 39). Megakaryocytes were also present 
in the sinusoids. In addition, an increase in the number of blood vessels was 
observed. None of the control groups or other experimental groups displayed this 
particular characteristic. A decrease in the number of liver cord cells
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(experimental group B1), compared to the controls, and was also noted. 
Megakaryocytes were also observed in the sections of liver from the B2 
experimental group (high dose, day 9 and 11 injected). Liver cord cells (B2 
experimental group) appeared disorganized with distended sinusoids between 
them (figure 40).
8.7 Skeletal development
Following skeletal staining, foetuses were examined with a stereomicroscope. 
Differences were found between the animals in the control and in the 
experimental groups.
8.7.1 Desmocranium of the rat foetus
Differences in bone thickness and cartilage formation were observed between 
the experimental and control groups (Table 3). The most obvious difference in 
thickness of bone in the skull region was the development and the thickness of 
the desmocranium. For descriptive purposes, the foetuses were either classified 
as having “thick” desmocrania (well developed, thick bone) or “thin” desmocrania 
(less well developed, thin bone). In control group A all the foetuses displayed thin 
desmocrania (figure 41) (100%) (4/4)(Table 3), while 62.5% (5/8) of foetuses in 
control group B displayed thin desmocrania. Two foetuses from control group B 
also displayed signs of immature bone development (bone did not develop). 
Group A1 (experimental) had 73% (11/15)(Table 3) of foetuses with thin
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desmocrania, while the remaining 27% (4/15) of foetuses displayed thicker bone 
of the desmocranium (figure 42). Experimental group A2 (high dose, continuous 
injections) displayed 60% (3/5) of foetuses with thick desmocrania, while the 
remaining 40% (2/5) of foetuses had thin desmocranial plates. In group B1 
(experimental) 4/8 foetuses (50%)(Table 3) were classified as having thick 
desmocrania. One foetus (experimental group B1) showed very immature bone 
development in the cranial region (figure 43). In experimental group B2, 100% 
(4/4) of foetuses displayed thick desmocranial plates.
8.7.2 Cartilage development in the nose
None of the foetuses in control groups A and B had cartilage present in the nasal 
region. In foetuses from experimental groups, it was observed that cartilage was 
present in the nose. Foetuses with cartilage were from experimental groups A1 
(13%), A2 (40%) and B2 (75%). No foetuses in experimental group B1 displayed 
signs of cartilage development in the nose.
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CA A1 A2 CB 81 b ;
DESMOCRANIUM:
THIN 100 73 40 62.5 50 0
THICK 0 27 60 37.5 50 100
CARTILAGE DEVELOP­
MENT IN THE NOSE 0 13 40 0 0 75
PRESENCE OF CARTILAGE:
INTENSE 0 0 40 0 0 75
MODERATE 0 47 20 37.5 0 25
EXTREMITIES 0 40 0 25 0 0
NO STAINING 100 13 40 37.5 100 0
VERTEBRAE:
ALMOST FUSED 0 53 100 25 62.5 100
WIDE OPEN 100 47 0 75 37.5 0
IMMATURE BONE 0 7 0 25 50 0
Table 3. Summary of bone and cartilage development in control and experimental foetuses.
8.7.3 Presence of cartilage in the skeleton of the developing foetus 
Cartilage development was divided into four categories. The foetuses were 
classified as having cartilage present throughout the axial skeleton (figure 44), 
present in pelvis, ribs and sternum only, present in the extremities or no cartilage 
present at all (figure 45).
No cartilage was present in foetuses of control group A. Thirty seven and a half 
percent (3/8) of foetuses in control group B had no cartilage in the axial skeleton, 
while 37.5% (3/8) had cartilage in the ribs. The remaining foetuses (25%, 2/8) in
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control group B showed cartilage in the lower limbs only. Forty-seven percent 
(7/15) of foetuses in experimental group A1 (low dose, continuous injections) 
presented with cartilage in the ribs, while 13% (2/15) of foetuses did not exhibit 
any cartilage development. The remaining 40% (6/15) of foetuses in the A1 
experimental group only had cartilage in the distal parts of the limbs. In 
experimental group A2, 40% (2/5) of foetuses presented with cartilage 
development in the whole axial skeleton, while another 40% (2/5) of foetuses 
presented with no cartilage. The remaining 20% (1/5) presented with cartilage in 
the ribs. The remaining foetuses of this group showed no cartilage development. 
In experimental group B1 (low dose, days 9 and 11 injected) 100% (8/8) of 
foetuses showed no cartilage development. In experimental group B2 (high dose, 
two injections) 75% (3/4) of foetuses showed cartilage throughout the whole 
body, while the remainder of foetuses (25%, 1/4) presented with cartilage in the 
ribs only.
8.7.4 Vertebrae
The vertebral columns of all of the foetuses were compared to see whether 
creatine had an effect on their development. Foetuses were divided into either 1) 
an almost fused vertebral column (where the pedicles of the vertebral body were 
almost fused to form the neural arch)(figure 46) or 2) a wide/open column (figure 
47) in which the pedicles are widely seperated.
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In control group A, the pedicles of the vertebral column were widely spaced in all 
of the foetuses (4/4). Twenty five percent (2/8) of foetuses in control group B, 
53% (8/15) of foetuses in the A1 group, 62.5% (5/8) of foetuses in B1 group and 
100% of foetuses in A2 (5/5) and B2 (4/4) dispayed pedicles that were almost 
fused.
8.7,5 Rudimentary ribs
Osteogenic cell clusters developed in 25% (1/4) of foetuses from control group A 
(figure 48) at the base of the 14th thoracic vertebra where the head of a rib 
usually develops. Sixty two and a half percent (5/8) of foetuses in control group B 
displayed osteogenic cell clusters in this position. In experimental group A1, 60% 
(9/15) of foetuses displayed cell cluster development in this position, while one 
foetus developed a full 14th extra rib on the left (figure 49). Osteogenic cell 
clusters were observed in 80% (4/5) of foetuses in the A2 experimental group at 
the T14 vertebral level, in 37.5% (3/8) of foetuses in experimental group B1, and 
in 50% (2/4) of foetuses from experimental group B2. One foetus in this group 
(B2) also developed an extra 14th left rib.
Derangement in the shape of the ribs occurred in 43% of foetuses in 
experimental group A1 (figure 50). No other foetuses (albeit the control or other 
experimental groups) were observed with the same derangement in the shape of 
the ribs. Usually ribs 6-12 were the most affected.
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3
Fig 3. Control foetus (group A) 
displaying no subcutaneous 
haematoma. Discolouration in 
abdominal region is due to 
normal development of the liver. 
Experimental foetus (group A2) 
displays haematoma covering 
most of the body.
Fig 5. Excessive 
haemorrhaging in the 
cranial region of 
embryo from 
experimental group B1 
(L=limb, E=ear). 6.4x
Fig 6. Crystal-like structures 
(arrows) spread over dorsum 
and abdomen of foetus in 
control group A. 6.4x 
stereomicroscope.
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Fig 7. Subcutaneous haemorrhaging in 
temporal region of foetus from 
experimental group A1 (arrows). 16x 
stereomicroscope.
Fig 8. Comparison of subcutaneous 
haemorrhaging between foetuses from 
control group A (right) and experimental 
group A2 (left).
Fig 9. Abnormal subcutaneous 
haemorrhaging in cranial region of foetus 
from experimental group A2 (arrows). 40x 
stereomicroscope.
Fig 10. Crystal-like structures (arrows) 
inside abdomen of foetus in A2 
experimental group. 40x 
stereomicroscope.
Fig 11. Comparison of foetuses from 
control group B vs experimental group 
BI.Note difference in body size.
Fig 12. Abdominal and temporal 
subcutaneous haemorrhaging 
(arrows) in foetus from experimental 
group B1. 16x stereomicroscope.
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Fig 13. Underdeveloped foetus (right) 
from experimental group B1 compared 
to foetus from control group B (left) at 
the same age. Note excessive 
subcutaneous haemorrhaging in 
experimental foetus. No haematoma 
was noted in the control foetus.
Fig 14. Absence of temporal artery 
(white line) in foetus from 
experimental group B2. Note 
abnormal superficial subcutaneous 
haemorrhaging in cranial region 
(arrows). 16x stereomicroscope.
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Fig. 17a. Representative 
section of the cortex (C) and 
medulla (M) of the kidney from 
a foetus in control group A. 
x100 Haematoxylin and Eosin.
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Fig 17b. Representative section of the cortex (C) and medulla (M) 
of the kidney from a foetus in experimental group A2. R= renal 
corpuscle. 100x Haematoxylin and Eosin.
Fig 18. Representative 
section of skeletal 
muscle obtained from a 
foetus in control group A. 
x400, Iron haematoxylin.
Fig 19. Representative 
section of skeletal muscle 
obtained from foetus in 
control group B. Both 
figures 18 and 19 display 
normal skeletal 
development for foetuses 
at the particular stage of 
development. x400, Iron 
haematoxylin.
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Fig 20.
Representative 
section of skeletal 
muscle from foetus in 
experimental group 
A1. Note striations 
(arrows). X400, Iron 
haematoxylin.
Figure 21. 
Representative 
section of 
skeletal muscle 
from foetus in A2 
experimental 
group. Fine 
striations 
(arrows) can be 
observed. x400. 
Iron
haematoxylin.
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Fig 22.
Representative 
section of skeletal 
muscle from 
foetus in 
experimental 
group B1. Some 
striations (arrows) 
can be identified. 
Tissue looked 
immature and not 
well developed, if 
compared to the 
A experimental 
groups. X400 iron 
haematoxylin.
Fig 23.
Representative 
section of skeletal 
muscle from foetus 
in experimental 
group B2. Note the 
immature developed 
muscle fibres as well 
as disorganized 
myoblasts. No 
apparent striations 
were observed, if 
compared to group 
A1 (experimental). 
X400 iron 
haematoxylin.
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Fig 24.
Representative 
section of 
pancreas from 
foetus in control 
group displaying 
absorption control. 
Anti-insulin serum 
pre-absorbed with 
insulin. X100.
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Fig 25. Representative 
section of pancreas 
(negative control) from 
foetus in control group A. 
x100.
51
The effect o f creatine on the developing rat foetus
Fig. 26. Section of 
pancreas from 
adult female rat 
that was used as 
positive control 
(insulin). X100.
Fig 27. Section of pancreas 
from foetus in control group 
A showing localization of B- 
cells (arrows). These cells 
will only develop into 
endocrine islet within the 
next day or two. 
Interference contrast, x100.
Fig 28. Localization of alpha 
cell s (arrows) in section of 
pancreas obtained from 
foetus in control group A. 
Interference contrast, x100.
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Fig 29. Localization of alpha 
cells (white arrows) around the 
periphery of an endocrine islet, 
found in the pancreas of a 
foetus from the A2 
experimental group. 
Interference contrast, x400.
Fig 30. Intense localization 
of beta cells from foetus in 
experimental group A2. 
Note endocrine islet 
formed, especially if 
compared to the pancreas 
of foetus in figure 27 
(control group) that was of 
the same age. Interference 
contrast, x400.
Fig 31 Lower
magnification of section (in 
figure 28) of pancreas 
from foetus in 
experimental group A2. 
Note amount of endocrine 
islets (beta cells) present 
in the small piece of 
pancreas. x100.
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Figure 32. Alpha cell 
immunolocalization 
(arrows) around periphery 
of endocrine islet (B1 
experimental group). 
Interference contrast, 
x100.
Figure 33. Intense 
immunolocalization of Beta 
cells in the endocrine islet (B1 
experimental group). 
Interference contrast, x100.
Figure 34. Beta cell 
immunolocalization in B2 
experimental animal 
pancreas. Interference 
contrast, x100.
Figure 35. Forming of 
alpha cells (arrows) 
around periphery of 
endocrine islets in B2 
experimental animal. 
Interference contrast, 
x100.
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Figure 36. Representative 
section of liver taken from 
foetus in control group A. 
x400, Haematoxylin and 
Eosin.
Fig 37. Representative 
section of liver taken from 
foetus in experimental 
group A 1 . Note distended 
sinusoids (S) and 
disorganized liver cord cells 
(L). Arrows=precursor 
blood cells. X400, 
Haematoxylin and Eosin.
Fig 38. Section of liver from 
foetus in experimental group 
A2. Note the increase in 
number in liver cord cells (L), 
precursor blood cells and 
wider sinusiods (S). X400, 
Haematoxylin and Eosin.
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Fig 39. Representative section of liver from foetus in experimental group B1. 
Very narrow sinusoids (S), megakaryocyte (arrow) and erythrocytes (E) in 
sinusiods (S). x400, Haematoxylin and Eosin.
Fig 40. Representative section of liver from foetus in experimental group B2. 
Arrows indicate megakaryocytes.Sinusoid (S). x400, Haematoxylin and Eosin.
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Figure 41. Foetus from 
control group A  that 
displays typical less well 
developed (thin) 
desmocranium.Note the 
difference in bone 
development between this 
foetus and foetus in figure 
39 (black arrow). 16x 
stereomicroscope. Alizarin 
red S and Alcian Blue.
Figure 42. Foetus from 
experimental group 
displaying well 
developed (thick) 
desmocranium 
compared to foetus in 
figure 38 (black arrow). 
Cartilage is present 
(white arrow). 16x 
stereomicroscope. 
Alizarin red S  and Alcian 
Blue.
Figure 43 shows 
foetus from 
experimental 
group B 1 , which 
is at a
comparable age 
to foetuses in 
figures 41 and 
42, with 
immature bone 
development. 16x 
stereomicroscope 
. Alizarin red S 
and Alcian Blue.
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Figure 44. 
Foetus from A2 
experimental 
group. 
Presence of 
cartilage (blue 
stained) very 
prominent in 
the ribs (red 
arrow), 
intervertebral 
discs (yellow 
arrows) and 
scapula (black 
arrow). Bone is 
stained red. 
6.4x
stereomicro­
scope. Alizarin 
red S  and 
Alcian Blue.
Figure 45 
shows foetus 
from a control 
group A. No 
cartilage was 
present in 
foetuses of 
this group. 
6.4x
stereomicro­
scope. Alizarin 
red S and 
Alcian Blue.
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Figure 46. 
Dorsal view of 
vertebral 
column of 
foetus in 
experimental 
group A2. 
Vertebral 
pedicles almost 
fused (white 
arrows). 
Vertebral 
bodies (V) can 
be observed. 
40x
stereo micro­
scope. Alizarin 
red S  and 
Alcian Blue.
Figure 47. Dorsal view of 
vertebral column from 
foetus in control group A  
Note the vertebral 
pedicles (white arrows). 
40x stereomicroscope. 
Alizarin red S and Alcian 
Blue.
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Figure 48. R e d  
stained bone 
(osteogenic) cell 
clusters (dorsal view) 
observed at the level 
of the 14th thoracic 
vertebra (black 
arrows). Vertebral 
bodies (V) and arches 
(A) can be observed. 
40x
stereomicroscope. 
Alizarin red S  and 
Alcian Blue.
Figure 49. 
Foetus from 
A1
experimental 
group that 
developed 14th 
rudimentary rib 
right (yellow 
arrow), and 
14th extra rib 
left (black 
arrow). 
Vertebral 
bodies (V) and 
arches (A) can 
be observed. 
40x
stereomicro­
scope. Alizarin 
red S and 
Alcian Blue.
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Figure 50. Foetus 
in A1 experimental 
group displaying 
derangement of the 
ribs (dorsal view). 
40x
stereomicroscope. 
Alizarin red S  and 
Alcian Blue.
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9. DISCUSSION
In this study, the effect of creatine on the development of the rat foetus was 
investigated to determine whether this substance is safe or whether it could be 
classified as a teratogenic substance when used during pregnancy.
9.1 Statistical analysis of length and weight of foetuses from the different 
control and experimental groups
9.1.1 Length
When a low dose of creatine was injected over a prolonged period (day 7-13) of 
development (experimental group A1), it did not have a statistically significant 
effect (P>0.05) on the growth and development of the foetuses when compared 
to foetuses in control group A. Foetuses that were exposed to a high dose 
(experimental group A2) of creatine over a prolonged period (day 7-13 of 
development) of time, had statistically significantly increased length when 
compared to foetuses in the A control group. However, when foetuses from 
control group A were compared to foetuses from control group B it was found 
that there was a statistical significant difference in length (P<0.01) between these 
groups. It appears that repeated injections of saline through days 7-13 of 
development had a negative influence on the development of the foetuses in the 
A control group. Foetuses in control group B, in which saline was injected on 
days 9 and 11 of development were significantly longer (P<0.01) than foetuses in
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the A control group. The foetuses in the B control group did not seem to be 
affected by the injections of saline. There was no statistically significant 
difference (P>0.05) between control groups A and experimental groups B1 (low 
dose, day 9 and 11 injected) and B2 (high dose, days 9 and 11 injected).
Experimental group A1 foetuses (low dose) were statistically significantly shorter 
in length (P<0.001) compared to experimental group A2 foetuses (high dose). 
Although both the experimental groups had the same amount of time of exposure 
to creatine, it appears as though the different dosages have different effects on 
the development of the foetus. An increase in dosage, surprisingly, had an effect 
on the length of the foetus, thus suggesting that if creatine is administered near 
the time of implantation, creatine does seem to have beneficial effect on the 
development of the foetus.
There are two possibilities that may promote the growth of the foetus. The one 
possibility is that nitric oxide may play a significant role in increasing growth 
hormone, while the other possibility is the effect of insulin on the developing 
foetus. It is well documented that nitric oxide (NO) stimulates growth hormone 
production and release (Wu and Meininger, 2000). Since arginine (Arg) is a 
substrate to NO as well as to creatine, an increase in creatine concentration may 
shift the balance of Arg in a way that more NO is formed. This is because more 
Arg is available for NO production, since creatine is supplemented exogenously. 
Due to exogenous creatine supplementation, an increase in creatine
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concentration is believed to have occurred (Wyss and Kadurrah-Daouk, 2000). 
More Arg was thus used in the production of NO, which in turn stimulated an 
increase in growth hormone. This explains why the foetuses in experimental 
group A2 had a statistically significant increase in length over that of foetuses 
from the other groups with the exception of control group B. The role of insulin on 
the developing foetus is discussed in section 9.1.3.
Foetuses from experimental group A1 showed a statistically significantly increase 
in length over that of foetuses from experimental group B1 (P<0.001). This may 
indicate that repeated injections and thus possible sustained, high levels of 
creatine played a role in the increase in length of the foetus.
Experimental group A2 was the group with the highest mean length. The only 
group that was not statistically significantly different in length (P>0.05) from group 
A2 was control group B. These results indicates that when a high dosage of 
creatine is administered over a prolonged period of time at repeated dosages, a 
probability exists that foetuses will grow more and show an increase in length. It 
is possible that an increase in growth hormone would lead to this effect (Wu and 
Meininger, 2000). The elevation in hormone levels is caused by an increase in 
NO, which can be brought about by elevated creatine levels due to creatine 
supplementation.
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Foetuses in control group B were statistically significantly longer than foetuses in 
experimental groups B1 and B2 (P<0.001). The reason why the foetuses were 
smaller in experimental groups B1 and B2 is that creatine may cause harm to 
certain metabolic processes during organogenesis. The NO-growth hormone 
hypothesis may not come into play when creatine is given at specific stages of 
organogenesis. Because creatine was supplemented on specific days i.e. days 9 
and 11 of development, and not repeatedly sustained (as in the A experimental 
groups), the foetus and the female rat may have had produce their own creatine 
endogenously. Arg may thus have been used in the production of creatine and 
not in the production of NO. This lead to the conclusion that there was no 
increase in growth hormone levels in these foetuses during this time. This data 
correlates well with the study that was undertaken by Badenhorst and Vorster 
(2000, unpublished data), which indicated that creatine did have a negative effect 
on the development of the chick embryo if administered during organogenesis.
9.1.2 Weight
When the weights of foetuses from different groups are compared to determine 
whether there are statistically significant differences between the control and 
experimental groups, it was found that creatine did not have as much influence 
on weight fluctuation as it had on length fluctuation. No significant difference in 
weight was found between control groups A and B, indicating that administration 
of saline over a prolonged period of time or during certain stages of 
organogenesis did not affect the mean weight of foetuses in those particular
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groups. When control group A was compared to experimental group A1, it was 
found that creatine at a low dose did not have a significant effect on the weight of 
foetuses (P>0.05). When control group A was compared to experimental group 
A2, a probable significant increase in weight (0.05>P>0.01) was found. This 
indicates that high doses of creatine given from day 7-13 of intrauterine life 
increased the weight of the foetuses. This however, does not mean that creatine 
is beneficial to the development of the embryo or foetus, since certain foetuses in 
this group also suffered either from subcutaneous haemorrhaging (foetuses were 
heavier than average) or were underdeveloped (foetuses were lighter than 
average). Control group A was also not significantly different (P<0.05) from 
experimental groups B1 and B2.
The mean weight of the foetuses in experimental group A1 was however 
significantly lighter than the mean weight of foetuses in experimental group A2 
(P<0.001). Thus, a higher dose of creatine over a prolonged time period appears 
to increase the weight of the foetuses significantly when compared to foetuses 
that received a low dose of creatine supplementation. Experimental group A1 
was not statistically significantly different from experimental group B1. This 
indicates that when foetuses are given the same dose of creatine over a 
prolonged period or during specific stages of organogenesis, no statistically 
significantly differences in weight occur.
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Experimental group A2, as mentioned above, was statistically significantly 
heavier in weight than control group A and experimental group A1. When 
experimental group A2 is compared to experimental group B2, a statistically 
significantly difference in weight was found (0.01 >P>0.001). It may be speculated 
from these results that the dosage of creatine appeared to have played a definite 
role. The closer to the time of implantation and the longer the creatine is 
administered, the heavier the foetus will be at term.
When experimental groups B1 and B2 are respectively compared to control 
group B, it can be seen that there was a statistically significantly difference in 
weight between control group B and B1 (P<0.01) and control group B and B2 
(P<0.05), with control group B having the highest mean weight. This would 
suggest that when creatine is administered during certain stages of 
organogenesis, independent of the dosage administered, the weight of the 
foetuses is decreased. It appears that creatine might have a delaying effect on 
development of the foetus if creatine is administered during particular stages of 
organogenesis.
It is well known that insulin plays an anabolic role during development and 
growth of the foetus (Korgun et al., 2003). Insulin also acts as an anabolic 
hormone that may stimulate protein synthesis (Augustin et al., 2003). If creatine 
is supplemented exogenously, the increase in creatine concentration can elicit an 
insulin response in the mother (Wyss and Kadurrah-Daouk, 2000). An increase in
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maternal insulin levels increases the rate of cleavage and development of the 
blastocyst as well as increasing the chances of the blastocyst to implant 
successfully (Augustin et at, 2003). It has also been shown that there is an 
increase in insulin receptors in the uterus, during the implantation period, and in 
the embryo (Kaye and Gardner, 1999). If the pregnant female has artificially 
enhanced insulin levels (due to exogenous creatine supplementation), the 
increased insulin and insulin receptors may trigger increased growth in the foetus 
(due to the anabolic properties of insulin). Although the foetus only starts to 
produce its own insulin on day 14 of development, the insulin serum (produced 
by the embryo) is too weak to have a significant effect on growth and 
development of the embryo (Louvi et ai, 1997). The embryo (and later foetus) 
thus utilizes insulin from the maternal source. This mechanism enables the 
mother to control the placental and foetal growth (Korgun et at, 2003), until the 
foetus has established its own endocrine system just before birth.
Since creatine was supplemented from day 7-13 of intrauterine development, an 
increase in maternal insulin levels promoted implantation and post-implantation 
growth of the blastocyst. Repeated injections of creatine kept the insulin levels of 
the female elevated. The elevated insulin (being an anabolic hormone) levels 
promoted growth in the embryo through the organogenesis period. However, in 
groups B1 and B2, creatine supplementation on days 9 and 11 of intrauterine 
development, may not have affected the insulin levels of the female significantly, 
thus not promoting enhanced growth compared to the foetuses in the A
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experimental groups. However, it appears that creatine did have a negative effect 
on the developing embryo if injected on these particular days of organogenesis. 
The timing of the injection may explain why the foetuses from experimental 
groups A1 and A2 had higher mean lengths and weights compared to the other 
control and experimental groups.
9.2 Surviving versus absorbed embryos
Three hundred and forty foetuses were collected from 40 pregnant adult females. 
An additional 116 absorbed foetal sites were counted in the uterine tubes of 
these pregnant females.
It was found that 21% (13/63)(control group A), 3% (3/92)(A1 experimental 
group) and 14% (11/78)(A2 experimental group) of foetuses were absorbed while 
in the B-groups 42% (31/74)(control group B), 28% (24/85)(B1) and 53% 
(34/64)(B2) of foetuses were absorbed (figure 2). It appears that prolonged 
administration of creatine (A experimental groups) (whether it is a low or high 
dose that is administered) causes less absorption than saline which was 
administered to control group A. In contrast, when creatine was administered on 
days 9 and 11 of development (B experimental groups), a definite increase in 
absorptions compared to the A groups occurred. This may indicate that creatine 
administration over a prolonged period of time (due to the effect of increased 
maternal insulin levels) increases the probability of successful events associated
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with the peri-implantation period (Kaye and Gardner, 1999). Compared to the B 
groups, administration of creatine during certain critical periods of organogenesis 
tends to increase the probability of mortality In vivo and absorption of a foetus.
Kimmel and Wilson (1973) intraperitoneally injected adult female pregnant rats 
with water on day 9 and on day 11 of development respectively. They observed 
that there was a 9% mortality and absorption rate of foetuses of pregnant female 
rats that were injected on day 9 and a 22% mortality rate of foetuses of pregnant 
female rats injected on day 11. They concluded that even a simple substance like 
water might induce absorptions. If these results are compared to control group A, 
it can clearly be seen that the saline group (20.6%, day 7-13 injected) has a 
decreased percentage in mortality in relation to the work of Kimmel and Wilson 
(1973). However, when comparing the work of Kimmel and Wilson (1973) to 
control group B (injected days 9 and 11) a 200% increase in resorption sites was 
found in the current experiment. Thus, it appears that when any solution is 
injected at a particular time of organogenesis, that solution might have a 
significant effect on the survival of the embryo/foetus. Kimmel and Wilson (1973) 
also injected pregnant female rats with Actinomycin D (10% of foetuses 
absorbed), Acetazolamide (6% of foetuses absorbed) and sodium Salicylate 
(26% of foetuses absorbed). When the data from Kimmel and Wilson (1973) is 
used as a measure to compare absorption rates of foetuses that were exposed to 
creatine, it appears that prolonged administration of creatine is not as harmful as 
Actinomycin D or sodium Salicylate to the foetus (A1, A2 experimental groups). It
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however, has a harmful effect on the foetus when injected on days 9 and 11 of 
development (B1, B2 experimental groups) (developmental time period of eye, 
brain and heart)(Baker etal., 1980).
Experimental group B2 (high dose, days 9 and 11 injected) had a 188% increase 
in foetal absorptions when compared to experimental group B1 (low dose, days 9 
and 11 injected). Experimental group B2 also had a 377% increase in foetal 
absorptions when compared to experimental group A2 (high dose, days 7-13 
injections) that had the same creatine dosage. This is a very high absorption 
percentage, suggesting that creatine might act once again as a teratogen on the 
developing embryo if given at a specific time during organogenesis. An increase 
in dose may also act is a teratogen to induce mortality. The higher the dose that 
is administered, the greater the chance that a foetus may be absorbed. Miller et 
al. (1993) found that cyclocreatine (a creatine analogue) can be lethal to the 
developing chick and rat. They found that increased dosages of cyclocreatine, 
administered to developing chick embryos and pregnant female rats, induced a 
higher mortality rate (chicks and rats foetuses) and a higher absorption rate (rat 
foetuses). When the present study is compared with the study of Miller et al. 
(1993), the results from the B groups, mirrors Miller’s findings. However, the 
results obtained from the A groups (control and experimental) suggest that 
creatine might be beneficial to the growth and development of the embryo/foetus 
if administered around the time of implantation. This increased and then
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sustained creatine concentration might have lead to an increase in insulin, which 
would benefit and enhance the growth of the developing embryo and foetus.
9.3 Macroscopic abnormalities
9.3.1 Subcutaneous haemorrhaging
Twelve foetuses from the total foetal group (340 foetuses) (0.04%) were found to 
suffer from abnormal subcutaneous haemorrhaging. In control group A it was 
observed that 4% of foetuses suffered from subcutaneous haemorrhaging. 
Experimental groups A1 and A2 each had 1.1% and 3% respectively of foetuses 
that suffered from subcutaneous haemorrhaging. In control group B, 2% of 
foetuses suffered from subcutaneous haemorrhaging, while 6.5% and 6.6% 
suffered from subcutaneous haemorrhaging in experimental groups B1 and B2 
respectively.
A possible explanation for why a small number of foetuses developed 
subcutaneous haemorrhaging may be attributed to the fact that arginine inhibits 
vasoconstriction (Wu and Meininger, 2000) by being a substrate to nitric oxide 
(NO). It is well documented that NO promotes angiogenesis, but also inhibits the 
aggregation of platelets and adhesion molecules of the vascular cells (Wu and 
Meininger, 2000). NO further inhibits the formation of smooth muscle and 
endothelin-1 release and plays a crucial role in vasodilatation (British 
Pharmacopoeia, 1953). Wyss and Kaddurah-Daouk (2000) found that NO inhibits
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the endothelial nitric oxide synthase (eNOS) process that is necessary for the 
maintenance of endothelial arterial walls. Inhibition of this process might lead to 
hypertension. Since arginine is a substrate for NO as well as for creatine, it is 
possible to speculate that a sudden increase in creatine concentration might shift 
the balance of Arg, with more NO being formed. This possible increase in 
creatine leads to a multitude of factors that might cause the subcutaneous 
haemorrhaging in the foetuses. Experimental groups B1 and B2 (injected on 
days 9 and 11 of embryonic development) might have underwent such an Arg- 
NO shift, with NO inhibiting eNOS. The increase in subcutaneous haemorrhaging 
that this shift brought along can clearly be seen in these groups (experimental 
groups B1 and B2). It thus appears that creatine supplementation may play a 
critical role in Arg-NO synthesis as well as NO metabolism. When this 
metabolism-synthesis equation is disturbed at certain stages of development, it 
has the potential to “induce” subcutaneous haemorrhaging in the embryo/foetus.
Foetuses from the different groups were compared and it was found that with an 
increase in the concentration of creatine, the incidence of subcutaneous 
haemorrhaging increased. No haemorrhaging was observed in the control 
groups. In the few foetuses that displayed signs of subcutaneous haemorrhaging, 
it was mostly localized in and around the abdominal area. However, foetuses 
from experimental group A1 had extensive subcutaneous haemorrhaging which 
stretched from the abdominal area into the thoracic area. These foetuses also 
displayed signs of haematomas in the temporal region, especially in the region
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where the superficial temporal artery is located. If the foetuses from group A1 are 
compared to the foetuses from group B1 (both groups had the same dose, but 
different times of injections), foetuses in experimental group B1 displayed 
subcutaneous haemorrhaging. Foetuses from experimental group B1 had larger 
areas of haemorrhaging, especially in the temporal region. It thus appears that 
an increase in dosage and repeated exposure to creatine increases the 
probability that a foetus will suffer from subcutaneous haemorrhaging.
When groups A2 (experimental) and B2 (experimental) are compared to each 
other, one would expect an increase in the severity of haemorrhaging (due to the 
fact that creatine supplementation would increase NO production, which in turn 
would inhibit eNOS production). In fact, it was observed that the A2 experimental 
group was the most affected. In this group, it was found that the haemorrhaging 
reached over the entire trunk and limbs, including the cranium. Although 
experimental group B2 had an increased number of foetuses (6.6%, 2/30) that 
were affected by the haemorrhaging, none of those foetuses displayed the same 
severity of haemorrhaging as those foetuses in experimental group A2. Again, it 
can be speculated that according to Miller et al. (1993), creatine and creatine 
analogs may have a toxic effect that induces subcutaneous haemorrhaging in the 
developing foetus.
Crystal-like structures were found in some of the foetuses. These structures were 
not found in control group B or experimental groups A1 and B2. However, control
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group A had one foetus (abdominal area) and experimental group B1 had one 
foetus that displayed these structures in the abdominal area. All the foetuses 
from the experimental A2 group that suffered from subcutaneous haemorrhaging 
also displayed crystal-like structures. In two of the most severe cases 
(experimental group A2) the crystal-like structures were also found in the 
temporal area. This may be a “precipitate” from one of the solutions used in 
preparation of the foetuses. However, the same solutions were made up fresh 
and used throughout the experiment. It appears that some internal mechanism 
was disrupted and caused these crystal-like structures. No explanation for this 
was found after an extensive literature search. Further research needs to be 
carried out in this regard to determine whether creatine disrupts any particular 
metabolic event.
While subcutaneous haemorrhaging was primarily observed in the abdominal 
area, it was also observed in the temporal area and cranium. The bigger the 
surface of the trunk that was covered with subcutaneous haemorrhaging, the 
more severe and excessive the haemorrhaging became. While no cases of 
temporal bleeding were observed in groups A and B (controls), there were two 
foetuses and one foetus respectively in groups B1 and B2 (experimental) that 
suffered from temporal bleeding. One foetus was found which lacked a temporal 
artery. All of the foetuses that suffered from subcutaneous haemorrhaging in 
experimental groups A1 and A2, also suffered from temporal bleeding. It may be 
postulated that when there is an increase in NO due to the increase in arginine,
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the excessive NO produced inhibits eNOS. eNOS is very important in 
maintaining arterial wall elasticity. Inhibition of eNOS by NO could have an 
artherosclerotic effect on the arterial walls. These arteries may lose their ability to 
handle the stress of hypertension and “burst”, thus creating a small haemorrhagic 
spot. NO also inhibits platelet aggregation (Wu and Meininger, 2000) thus 
causing that the foetus might bleed to death in vivo.
As the dosage of creatine increases, it seems that subcutaneous haemorrhaging 
affects the whole foetus from abdomen to cranium.
9.3.2 Underdeveloped foetuses
A number of underdeveloped foetuses (underdeveloped = behind normal 
developmental stages and which weighed significantly less than the group mean 
and was of a shorter length than the mean length of the group) were observed. 
Interestingly, it was control group A that had the most underdeveloped foetuses 
(28%) of all the groups, followed by experimental group B1 (19.7%) and 
experimental group A1 (4.5%). Control group B and experimental groups A2 and 
B2 did not have any underdeveloped foetuses. It could be argued that the 
underdeveloped foetuses are just at the extreme end of the range. However, a 
pilot study done by Badenhorst and Vorster (2000, unpublished data) showed 
that creatine inhibited growth in the developing chick embryo, indicating the 
involvement of creatine in inhibition of embryonic growth.
While group B2 did not display underdeveloped foetuses, it is possible that those 
foetuses that were not developing well were eventually absorbed as 53% (34/64)
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of foetuses were absorbed in this group. The work of Miller et al. (1993) 
illustrated that an increase in dosage of a creatine analogue increased in vivo 
foetal mortality rates.
9.4 The effect of creatine on histological structure
Histology was carried out on the kidneys, skeletal muscle, pancreas and liver of 
foetuses from all groups. These organs were chosen since they are primary 
production sites of creatine (Walker, 1979; Horn et al., 1998). Skeletal muscle 
was also utilized since it stores 95% of the total creatine content of the body 
(Persky and Brazeau, 2001). Each organ was studied and comparisons were 
made between the experimental and control groups.
9.4.1 Kidneys
The renal corpuscles of the kidney in the different groups (groups A and B, 
experimental and control) were well developed, as were the collecting tubules. 
Anecdotal reports (Robinson et al., 2000; Wyss and Kaddurah-Daouk, 2000; 
Brudnak, 2004) claim that creatine might influence the filtration apparatus of the 
kidney and might result ultimately in kidney failure. If creatine had a significant 
effect on the filtration apparatus and cellular structure of the kidney, it would 
manifest itself especially during organogenesis of the kidney. It appears that 
creatine did not have a significant effect on the development of the kidney in the
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foetuses of this study, although the ultrastructure of the cells and the filtration 
barrier was not studied.
9.4,2 Skeletal muscle
Control groups A and B had normal striations and well developed muscle fibres. 
Very precise “A” bands were observed in these groups as well as the interlinking 
“I” bands. When skeletal muscle sections from control animals were compared 
with those from experimental group A1, the tissue appeared to be very similar. 
However (although not quantitated), when experimental group A2 was compared 
to control group A, it appeared that there was an increase in the number of 
muscle fibres in group A2. Skeletal muscle creatine content is boosted by factors 
that play a role in glucose metabolism (Weiss et at, 2002). Factors such as 
insulin and insulin-like growth factor (IGF) are involved. It appears that creatine 
administered over a period may cause the increased formation of myofilaments, 
thus leading to the increase in striations in the developing myoblasts. This could 
be attributed to the anabolic effects of insulin (Augustin et a i, 2003). Mujika and 
Padilla (1997) found that an increase in creatine content and creatine 
concentration (due to creatine supplementation) induces increased protein 
synthesis in skeletal muscle.
The skeletal muscle fibres of experimental groups B1 and B2 were not as well 
developed as those of experimental groups A1 and A2. Although not quantitated, 
more immature fibres were observed in experimental groups B1 and B2.
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Once again, it is postulated that the sudden increase in creatine concentration 
(due to creatine supplementation) in the myoblasts at critical stages (days 9 and 
11) of development might cause a shift in the Arg-NO metabolism. This in turn 
may increase the amount of NO produced. NO inhibits mitochondrial function by 
destabilizing the mitochondrial membrane potential (Gross et al., 1996), thus 
probably explaining why the myoblasts in experimental groups B1 and B2 were 
underdeveloped. The reason why the muscle fibres in A1 and A2 were better 
developed than their counterparts in the B groups could be attributed to the 
anabolic properties of insulin (Augustin et al., 2003), as well as the increase in 
growth hormone (due to excessive NO production). Mujika and Padilla (1997) 
found that exogenous creatine supplementation increased muscle fibre diameter, 
whereas creatine analogs fed to rats for a period of time, decreased fast-twitch 
muscle fibre diameter (Wyss and Kadurrah-Daouk, 2000).
9.4.3 Pancreas
When the histology of the pancreas of the control groups was compared to those 
of the experimental groups (A and B), it was found that there was a more intense 
localization of the contained protein in the a- and p cells in experimental groups 
than in the control groups.
Rail et al. (1973) found that rat foetal pancreas starts to produce its own insulin 
after 14 days of development. However, the serum levels of insulin are very low 
between days 14 and 18 of development. Ninety five percent of insulin is
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accumulated in the p cells between days 18 and 22 (birth)(Rishi et at, 1969; Rail 
et a!., 1973). The serum concentration of insulin is increased threefold during 
these four days (Kervan and Gerard, 1974). The rat embryo thus receives its 
insulin for the whole period of gestation from the maternal source. Exogenous 
creatine supplementation elicits a direct insulin response (Wyss and Kadurrah- 
Daouk, 2000), thus the pregnant mother would have elevated insulin levels 
circulating in her blood (Wyss and Kadurrah-Daouk, 2000). The purported raised 
insulin levels in the female of this study may have an enhancing effect on the 
development of the pancreas, causing the pancreas to be “ahead” of 
development. In this study, foetuses from experimental groups had pancreata 
that were ahead of development, while the pancreata of control group foetuses 
were at the normal stage of development. This may explain why the experimental 
groups had a more intense localization of insulin protein in the p- cells than the 
control groups. More insulin may have been accumulating in the pancreata of the 
animals in the experimental groups during days 18 to 20 of development 
because the development of the pancreata of foetuses in the experimental 
groups was enhanced by the anabolic properties of insulin.
It is in the very late stages of rat pancreatic development that typical islet 
formation is seen, with p cells in the core of the islet and other endocrine cells 
spread around the periphery (Herrera et ai, 1991; Louvi et ai, 1997). When The 
present study is compared to the that of Herrera et at (1991) and Louvi et ai 
(1997), typical islets had not formed in the pancreata of control foetuses, while
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the pancreata of the experimental groups appeared to be “ahead” of their stage 
of development. This is possibly due to the effect of maternal insulin on the 
developing pancreas. It thus appears also that creatine supplementation has a 
positive effect on the development of the pancreas, especially the endocrine 
cells.
9.4,4 Liver
In a toxicology study, the liver would be the first organ usually affected at a 
cellular level, due to its function as a detoxifying agent. The histology of the liver 
from control groups A and B appeared to be similar, with an abundance of liver 
cord cells as well as relatively wide-open sinusoids. Precursor blood cells were 
found in the sinusoids. When the control groups were compared to the 
experimental groups, it was found that creatine appeared to negatively affect the 
development of the liver. In all the experimental groups (although not 
quantitated), there was a decrease in the number of liver cord cells compared to 
control groups. Fewer precursor blood cells were present in the experimental 
groups compared to the control groups. The sinusoids in the experimental groups 
were also wider relative to those of the control groups. This may be attributed to 
the fact that there is a decrease in number of liver cord cells, thus making the 
sinusoidal spaces look wider. An exception to the abovementioned statement 
was the liver of animals from experimental group B1, which showed a number of 
altered features. Erythrocytes were found in the sinusoids and it appeared that 
there was an increase in blood vessels in the sections of liver examined. The
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sinusoids of this group, contrary to the other experimental groups, were very 
narrow. Megakaryocytes were found in the liver sections of experimental groups 
B1 and B2, but no megakaryocytes were observed in any of the other groups. In 
the B2 group (experimental) the liver cord cells appeared to be disorganized. The 
present research supports work done by Hatano et al. (1996) and Kanazawa et 
at. (1998). Both groups of researchers injected mice with D-galactosamine to 
induce hepatic injury. Hatano et al. (1996) found that the effects of D- 
galactosamine were reduced if mice were supplemented with creatine. 
Kanazawa et al. (1998) observed that 48 hours after D-galactosamine 
administration, 80% of mice supplemented with creatine were alive, compared to 
the 100% mortality rate of mice in the group not supplemented with creatine. It 
appears that the longer the developing liver was exposed to high creatine 
concentration levels in this study, the less damage there was to the liver.
9.5 SKELETAL DEVELOPMENT
The desmocranium of the foetuses from all groups were compared to see 
whether creatine had a significant impact on the development of bone. Thin 
desmocrania were observed in control groups A and B. When the control groups 
were compared to the experimental groups, thicker desmocrania were observed 
in all the experimental groups. Thus, it appears as if creatine may increase the 
rate of bone growth. The A1 group (experimental) had a 27% (4/15) increase in 
the number of foetuses with thick desmocrania and the A2 group (experimental)
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a 60% (3/5) increase in the number of foetuses that presented with thick 
desmocrania. B1 and B2 groups [50% (4/8)and 100% 4/4) respectively] exhibited 
the same pattern as was found in the A experimental groups. From this data, it 
can be speculated that creatine appears to influence the development of the 
cranial plates and in particular, the desmocranium, in such a way as to stimulate 
bone growth in the developing rat foetus. In addition, the time of creatine 
administration does not play a role in this regard, since foetuses in both the A2 
and B2 groups had thicker desmocrania.
Endochondral and intramembranous ossification takes place to form bone in the 
rat foetus from early stages of development until birth (Baker et at, 1980). At the 
particular stage of skeletal development observed in foetuses in this study, 
cartilage is not yet present in the ribs, vertebral bodies or limbs of the foetus. 
Cartilage formation (in the ribs, vertebral bodies, limbs) takes place from day 20 
of development until birth (Louvi et al., 1997; Menegola et a i, 2001). Thus, at the 
particular stage of development represented by the foetuses in this study, an 
axial skeleton would be present, but no cartilage would yet exist in the ribs and 
sternum.
The development of cartilage was divided into four categories for this study. 
When the foetuses from the different groups were compared, the foetuses were 
classified as having cartilage throughout the axial skeleton, present in the pelvis, 
present in the ribs and sternum only, present in the extremities or no cartilage
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present at all. In control group A, none of the foetuses (4/4) exhibited any 
cartilage, while in control group B only 37.5% (3/8) of foetuses had no cartilage 
present. The remainder of foetuses in this group showed cartilage in the ribs and 
sternum (37.5%, 3/8) and in the extremities (25%, 2/8).
There was a definite increase in the amount of cartilage from experimental group 
A1 to experimental group A2 and from B1 to B2. There was no cartilage present 
at all in the foetuses (8/8) in experimental group B1.
It was consistently found that in the control groups, the pedicles of vertebrae 
were widely spaced and not fused, while in experimental groups A1 and B1 the 
pedicles of the vertebrae were almost fused in 53% (8/15) and 62.5% (5/8) of the 
foetuses respectively. In experimental groups A2 and B2, all the foetuses 
observed had pedicles of vertebrae that were much closer to fusion or fused. In 
this particular part of the study, the time of administration did not play a 
significant role, but rather the dosage of creatine that was administered appears 
to have affected development. The higher the dosage that was administered, the 
higher the incidence of closely placed pedicles.
The fact that 50% (4/8) of foetuses in experimental group B1 showed immature 
bone development underlines the fact that some internal mechanism may have 
been disrupted. Due to the fact that 50% of the foetuses displayed immature 
bone development, it also explains why 100% (8/8) of the foetuses in this
84
The effect of creatine on the developing rat foetus
particular group did not display any presence of cartilage. Foetuses with 
immature/delayed bone development were found in control group B (25%, 2/8) 
and experimental groups A1 (7%, 1/15) and B1 (50%, 4/8).
Kimmel and Wilson (1973) did a study to determine whether a substance could 
induce extra rib formation (rats have 13 pairs of ribs). They defined a 14th 
rudimentary rib as one that is less than half the length of the 13th rib. A 14th rib 
that is longer than 50% of the 13th rib would be termed an extra rib (Kimmel and 
Wilson, 1973). In the present experiment, small groups osteogenic cells were 
observed at the level of the 14th thoracic vertebra, where the head of the rib 
would normally attach to the vertebra. In control group A, 25% (1/4) of foetuses 
showed osteogenic cell cluster at this level, compared to 62.5% (5/8) of foetuses 
in control group B. No extra 14th rib was observed in control group A, while one 
foetus in control group B had an extra 14th rib. Interestingly, experimental groups 
A1 and A2 also displayed 60% (9/15) and 80% (4/5) respectively of foetuses that 
had an osteogenic cell cluster. Forty percent (6/15) of foetuses in experimental 
group A1 also developed an extra 14th rib. In experimental groups B1 and B2 it 
was observed that each displayed a 36% and 50% formation of cell clusters 
respectively, while experimental group B2 had 25% of foetuses that formed a 14th 
extra rib. According to this information and the data collected by Kimmel and 
Wilson (1973), rats do have the ability to form a 14th rib if exposed to a foreign 
substance, which in this case could also have been induced by saline (see 
control group B).
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Creatine analogs (i.e. cyclocreatine) inhibit cartilage formation given to rat 
foetuses in vivo and chicken chondrocytes in vitro (Wyss and Kadurrah-Daouk, 
2000). Creatine might stimulate tumour growth (Wyss and Kadurrah-Daouk, 
2000), since it has been shown that creatine analogs can inhibit tumour growth 
(Miller et a!., 1993). It thus appears that creatine administration increased the 
rate of cartilaginous growth in the present study. In a study done by Louvi et al. 
(1997), they cross bred mice until they had a wild type group, an Ir (insulin 
receptor deficient) group, an Ig rlr (insulin-like growth factor 1 receptor deficient) 
group and an Igf2r (insulin-like growth factor 2 receptor deficient) strain. Females 
from each group were made pregnant and sacrificed at certain stages of 
development; foetuses were collected and underwent skeletal staining. It was 
found that mice foetuses that had no insulin receptors, as well as the mice 
foetuses that were deficient in insulin-like growth factor 1 receptors, suffered from 
delayed growth and skeletal development. The wild type foetuses were the 
biggest and most advanced in skeletal development. They concluded that if there 
were a decrease in insulin or insulin receptors, skeletal growth would be delayed. 
However, an increase in insulin concentration (maternally, due to exogenous 
creatine supplementation) may induce enhancement of growth of the foetus, 
especially the skeletal system. This may explain the results of the present study 
in which creatine exposure (repeated or day 9 and 11 injected) may have 
increased insulin levels (maternally), thus influencing the growth of the foetus 
positively. This may have led to an enhanced rate of growth of the foetal skeletal 
system. To explain this further, when the foetuses from control and experimental
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groups were compared, it was observed that normal skeletal ossification took 
place in the region of the ribs, indicated by a prominent primary ossification 
centre. However, it was observed that the experimental groups (A and B) had 
extensive costochondral cartilage formation while costochondral cartilage 
formation in the control groups was absent. When these observations are 
compared to the work done by Louvi et a!., (1997), it appears that the 
experimental groups had enhanced cartilage formation and were at least one to 
two days ahead of development of that of the control groups. It was observed 
that there was an increase in the number of osteogenic cell clusters (at T14 level) 
from the control group A to experimental groups A1 and A2; supporting the fact 
that creatine did have an enhancing effect on bone development. This may 
indicate that exogenous creatine supplementation may have elicited an insulin 
response and that the elevated insulin levels may have enhanced skeletal growth 
in these foetuses.
10. CONCLUSION
It appears that creatine has both a positive effect and a negative effect on the 
developing rat foetus. Negative effects include subcutaneous haemorrhaging, 
underdevelopment of foetuses, delay skeletal muscle development (B1 and B2 
experimental groups) as well as a decrease in cord cells in the liver of animals 
from the experimental groups. However, in the adult, creatine stimulates protein 
synthesis in skeletal muscle. Which is contrary to what was found in experimental
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groups B1 and B2. Further research needs to be carried out in order to explore 
the opposite effects on skeletal muscle in the foetus and the adult.
Positive effects of creatine include an increase in bone (thickness) and cartilage 
formation, enhanced p-cell formation in the pancreata of animals from 
experimental groups, as well as increased mean weights and lengths.
The positive effects of creatine may be attributed to increased levels of insulin in 
the pregnant female rat (due to creatine supplementation) and the anabolic 
properties of insulin. This effect could be studied further by investigating serum 
levels of insulin and creatine in the pregnant rats undergoing creatine 
supplementation. It appears that some mechanisms, however, may have been 
disrupted during certain early stages of development (day 9 and 11 injected 
foetuses) thus inducing the negative effects. These mechanisms, however, 
cannot be speculated on here.
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APPENDIX A
All necessary documentation pertaining to animal ethics are presented in this 
appendix.
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STRICTLY CONFIDENTIAL
UNIVERSITY OF THE WITWATERSRANP, JOHANNESBURG 
ANIMAL ETHICS SCREENING COMMITTEE
CLEARANCE CERTIFICATE NO
2003 48 3
APPLICANT: Henk Badenhorst
DEPARTMENT: School of Anatomical Sciences
PROJECT TITLE : The Effect of Creatine on the Developing Rat Foetus
Species Number Expiry Date
Sprague dawlev 40 2005
i) Approval is hereby given for the experiment described in the above application.
The use of these animals is subject to AESC Guidelines for the use and care of animals, is limited to the 
procedures specified in the application form, and to:
APPROVED subject to:
-using sterile injections ®
-demonstrating the injection technique to the CAS staff 
-discussing the route of administration with Professor Norton 
-providing information on the method of euthanasia to be used 
- the fate of 4fmales (to CAS staff)
SIGNED . / f .
'Chairman: r i r i l l J  f n m m i t T P p ' l
DATE: 2 June 2003
ii) I am satisfied that the persons listed in this application are competent to perform the procedures therein, 
in terms of Section 23(1 )(c) of the Veterinary and Para-veterinary Professions Act (19 of 1982)
DATE: 2 June 2003
NOTE:
First-time users of the CAS should contact the Director of the CAS in order to familiarise themselves with the 
facilities available, and the procedures required by the CAS for the carrying out of experiments.
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e.
f.
g-
h.
Number and species of animals originally approved:
Number of additional animals previously allocated on M&Es:
Total number of animals allocated to the experiment to date:
Number of animals used to date:
i. Specific modification / extension requested:
We would like to carry out vaginal smears on the female rats each day to confirm the stage of the 
oestreous cycle.
j. Motivation for modification / extension:
More accurate way to determine in which stage of oestreous the female is in and when the best time is
November 2000
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ANIMAL ETHICS EXTENSION ON NR 2003/48/3
SPECIFIC MODIF1CAT1QN/EXTENSION
16 SD females required
MOTIVATION FOR MODIFICATION/EXTENSION
New literature suggests that the normal maintenance dose of creatine is anything 
between 3-7 grams per day. In the current experiment I am using a maintenance 
dose of 15 grams per day, according to older literature. I would like to investigate 
what the difference between the two doses could be and for this I would require 
15 animals. One female is also needed as one excisting female was accidentally 
injured by a male and had to be euthanased.
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APPENDIX B
Shorr staining technique (Drury and Wallington, 1980)
500 ml 50% ethyl alcohol 
2.5g Biebrich scarlet 
1.25g Orange G 
0.375g Fastgreen FCF 
7g Phosphohomolybdic acid 
5ml Glacial acetic acid
Allen’s fixative (Gray. 1953)
75ml saturated aqueous picric acid 
25ml (40%) concentrated formalin 
5ml glacial acetic acid 
1 gr urea/100ml fixative
Combine solutions to form 100ml of fixative. Mix urea into solution and dissolve 
urea completely.
A derivative of this method is Allen’s fixative, where 1 gr urea/100ml fixative is 
dissolved in the fixative. The reason for use of the urea is that it can prolong the
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fixation period indefinitely without serious harm (swelling, hardening) to the 
tissue.
Formic acid-formalin decalcification (Bancroft and Gamble. 2002)
10ml 90% stock formic acid 
5mi 40% formalin
Distilled water to make up to 100ml.
Immerse embryo in solution and leave for at least 72 hours for solution to 
penetrate embryo fully. After 72 hours, prepare a fresh solution and immerse the 
embryo in the fresh solution. Two hours after immersion of the embryo into the 
fresh solution, can an endpoint test be done. If the solution turns cloudy during 
the endpoint test, there is still calcium present in the foetus. If the solution stays 
clear, all the calcium has been dissolved and the embryo is ready for processing.
Formic acid is a weak acid and was used in this experiment to decalcify the foetal 
bone. Formic acid does not cause extensive swelling or harm to the bones or 
tissue like strong acids (HCI or nitric acids), but takes longer to decalcify the 
specimen.
Alcian Blue and Alizarin red S skeletal staining method (Meneqola et 
al.. 2001)
Acid staining solution (pH 2.8)
0.14% Alcian blue dissolved in ethanol (70%), 5 parts
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0.12% Alizarin red S dissolved in ethanol (96%), 1 part 
Glacial acetic acid, 8 parts 
Ethanol (70%), 50 parts
Basic staining solution
0.7% KOH dissolved in distilled water, 250 parts 
0.5% Alizarin red S dissolved in distilled water, 1 part
Clearing solution
Ethanol (70%), 2 parts 
Glycerine, 2 parts 
Benzyl alcohol, 1 part
Conservation solution
Ethanol (70%), 1 part 
Glycerine, 1 part
Foetuses were immersed in 4% NaCI overnight. The following day foetuses were 
then skinned and eviscerated. Dorsal muscles were gently removed as well as 
the heat pad that is situated between the scapulae.
Embryos were then immersed in acid staining solution (24 hours) and then 
dehydrated in 96% alcohol (24 hours). Embryos were then immersed in the basic
107
The effect of creatine on the developing rat foetus
staining solution for at least 30 hours. The solution must be renewed at least 
three times. The KOH causes maceration of the soft tissue.
After the basic staining solution, the embryo was then placed in the clearing 
solution. This solution clears and hardens the tissue. A skeletal structure can 
now be seen. In the final step, the foetus was then placed in conservation 
solution.
Immunocytochemistry
Notes
Primary and secondary antibodies were made up in a special diluent (see diluent 
for antiserum).
Each section required approximately 30ul of antibody.
Diluent for antiserum 
100 ml Tris/saline
0. 25g sodium azide (this must be added to Tris in fume cupboard)
5mg bovine serum albumin
40 mg E.D.T.A.
1ml swine serum
Tris solutions
1. Tris/HCI (0.05 M Tris buffer pH 7.6)
Stock solutions that will be needed is 1 M Tris and 1 N HCI.
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Mix 100ml (Tris) to 76.8ml of the HCI. The pH must then be adjusted to 7.6 (it 
might be necessary to add more HCI). Add distilled water until the solution is 
made up to 2 litres.
Tris/saline (0.95% NaCI. 0.05 M Tris/HCI at pH 7.6)
Dissolve 42.75g NaCI in 4.5 litres distilled water. Add 500ml Tris/HCI to make up 
5 litres of solution.
DAB
1mg of DAB weighed into new bijou bottle.
When second day starts, put 29ml (distilled water) in fridge (4°C).
Add 2ml of Tris/HCI to DAB in bijou bottle.
Add 1ml of 30% Perhydrol (Hydrogen peroxide) to the 29ml distilled water to 
make up a 30 ml 1% peroxide solution. Mix well.
Add 20ul of 1% perhydrol to DAB/Tris/HCI solution and mix well.
Iron haematoxylin
Iron Alum solution 
5-gram iron alum 
100 ml distilled water
Haematoxylin 
0.5gram haematoxylin
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100ml 90% ethanol 
Notes
Dewax sections in xylene and rehydrate to water. Place in iron alum (mordant) 
for 1 hour. Rinse in distilled water. Immerse sections into 0.5% haematoxylin 
(depending on the fixative) for at least one hour (Bouin’s = one hour, Helly’s = 
three hours). Wash sections in running tap water and put in distilled water. 
Differentiate each section separately (microscopically) in 5% iron alum until 
structures are clearly desired. Wash in tap water for ten minutes. Dehydrate 
through graded series of alcohols to absolute alcohol, immerse in xylene and
mount in entellan.
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a. nn.iutsi'Ku:)
[OESTRUS
2" tv. ■D ioestrus
:merous nucleated cuboidal cells, 
e cornified polygonal cells, 
undance of leucocytes.
( i i i )
Abundance of elongated cornified cells 
Some nucleated cuboidal cells. 
Occasional leucocvtes.
; Mid-
Numerous nucleated cuboidal cells.
Occasional elongated»polyccnal cornified cell 
some leucocytes.
D. PROESTRUS
Polygonal cornified cells numerous. 
Some, nucleated cuboidal cells.
Very few leucocytes.
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APPENDIX D
Days and events of organogenesis (Baker et at., 1980)
Day 7
Gastrulation stage: implantation of the zygote almost completed.
Cardiac region: mesodermal cardiogenic primordia (paired) develop.
Day 8
Primitive streak: amniotic and ectochorionic cavities connected, primitive streak 
develops.
Circulatory system: mesodermal cardiogenic primordia (paired) are developing.
Day 9
Digestive system: Initiation of development of foregut.
Circulatory system: fusion of cardiogenic primordial, formation of endothelial cells 
between splanchnic mesoderm and endoderm. Initiation of myo­
cardial contractions in partly fused heart (still tubular). Primitive 
bulboventricular rudiment formed from cardial myoblasts and 
initiation of myocardial contractions.
Day 10
Neuruia: Formation of somites 5-12 and first visceral arch and regression of the 
peripheral yolk sac. Embryo is bent dorsally. Formation of visce­
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ral arches I and II (recognizable), placenta of yolk sac. Embryo 
folds ventrally.
Digestive system: rupturing of oral membrane and formation of liver primordium. 
Yolk stalk tapers down to slim tube.
Circulatory system: Tubular heart in S-shape, formation of atrial and bulbo- 
ventricular zones and aortic arch l-lll, development of sinus 
venosus, ventricular loop, umbilical veins and atrium. Heart 
starts pumping, circulation through body established.
Day 11
Neurula: Lower thoracic somites form and yolk stalk closes (15 somite level).
Buds of arm and leg develop and primitive streak recedes 
Digestive system: Liver and dorsal pancreas develop together with laryngo­
tracheal groove. Closure of vitteline duct and formation of cloaca 
and tailgut. Stomach is longitudinal and trabeculae forms in liver. 
Formation of cloacal membrane.
Circulatory system: Definite aortic arches l-lll and formation of interventricular 
sulcus. Aortic arch I start regressing, aortic arch IV develops. Left 
and right heart chambers just recognizable as separated. Aortic 
arch IV still small while aortic arch I regress more. Aortic arch II 
starts regressing. End of day 11, aortic arches III and IV well 
developed
while irregular aortic arch V appears.
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Muscular system: Myotomes made up of longitudinally arranged lengthened 
myoblasts.
Day 12
Tail bud embryo: Formation of somites 32-40 as well as deep cervical sinuses, 
olfactory pits and umbilical herniation.
Complete embryo: Vascularization of limb buds and development of brachial 
nerves in upper limb.
Digestive system: Pharyngeal pouches undergo changes. Numbers. 1 and 3 
contact ectoderm while number 2 bursts into the visceral 
groove. Ultimobranchial body develops in pouches 4-6. 
Development of stomach, hepatopancreatic duct and duodenum. 
Ventral and dorsal pancreas (with duct) develops. Tongue develops 
while the trachea separates from oesophagus. Liver with deep cut 
lobes while stomach takes on oblique shape. Regression of tailgut.
Circulatory system: Formation of atrial septum and atrioventricular canal, large 
aortic arches IV and V present. Aortic arches I and II completely 
disappeared. Interventricular septum forming together with atrio­
ventricular cushions and septa in the heart. Pulmonary vein opens 
into left atrium. Aortic arch V regresses, collection of vitteiine and 
umbilical veins into hepatic vein. Fusion of ventral and dorsal atrio­
ventricular cushions. Atrial septum still incomplete, but forming
foramen ovale.
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Muscular system: Development of spindle-shaped myoblasts.
Endocrine glands: Formation of dorsal and ventral pancreatic buds. Pancreatic 
ducts develop.
Day 13
Metamorphosing embryo: Cartilage beginning to develop in distal part of limbs. 
Digestive system: Fusion of ventral and dorsal pancreas while primary duct 
disappears. Single intestinal loop recognizable.
Circulatory system: Aortic trunk beginning to separate into pulmonary and 
systemic parts, aortic arches same as day 12. Foramen ovale 
present and formation of auricles occurring. Left and right 
separation of heart nearly complete.
Endocrine glands: Dorsal and ventral pancreata fuse, complete with islets and 
acini. Pancreas also sprouts tubules.
It must be mentioned in that cartilage development in the distal parts of the limbs 
only start on day 13 of development and skeletal cartilage of the ribs on day 14 of 
development, while crystallization of the cartilage to bone only starting to occur 
from day 17 and onwards.
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APPENDIX E
Statistical analysis
All statistical calculations as well as all raw data is included in this section.
An alpha level of (P<0.05) was used in all the calculations to determine whether 
there is a significant difference between all the groups.
11 6
LENGHT OF FOETUgiSSqffftfflBfteBafr16 on the developing rat foetus
Group A (day 7-13 consecutive injections)
Foetus nr Control A Foetus nr Exper. A1 Foetus nr Exper. A2
Saline ri5q/davl r30q/davl
E1-1 34.65 A1-1 42 G3-1 39.2
E2-1 47.45 A1-2 43 G3-2 36.1
E2-2 41.25 A1-3 43.8 G3-3 39.1
E2-3 45 A1-4 39.2 F1-1 36.05
E2-4 40.85 A1-5 36 F1-2 39
E2-5 41.85 A1-6 41.8 F1-3 37.2
E2-6 42.6 A1-7 43 F1-4 41.35
E2-7 43.5 A1-8 40 F1-5 38.1
E2-8 40.15 A1-9 40.8 F1-6 37.2
E2-9 47.25 A1 -10 42.1 F1-7 39.55
E2-10 46.95 A1-11 42.7 F1-8 38.9
E2-11 47.15 E3-1 38.2 F1-9 38.15
E2-12 46.25 E3-2 39.9 F1-10 37.25
A5-1 40.6 E3-3 41 F1-11 41.25
A5-2 42.25 E3-4 38.55 F1-12 39.05
A5-3 41.55 E3-5 40.05 F 1 -13 38.25
A5-4 42.5 E3-6 41 F1-14 39.2
A5-5 42.5 E3-7 38.47 C3-1 45.4
A5-6 39.45 E3-8 38.9 C3-2 42.7
A5-7 44.05 E3-9 37.3 C3-3 42.35
A5-8 39.2 E3-10 42.8 C3-4 44
A5-9 41.4 E3-11 38.55 C3-5 46.05
A5-10 43.95 E3-12 42.25 C3-6 47
A5-11 40.15 E3-13 39.6 C3-7 41.35
A5-12 37.25 E3-14 39.55 C3-8 45.2
B5-1 31.75 E3-15 37.85 C3-9 47.5
B5-2 27.75 E3-16 38.45 C3-10 43.85
B5-3 32 E3-17 38 C3-11 42.1
B5-4 31.4 H3-1 33.6 C3-12 46.2
B5-5 30.45 H3-2 37.9 C3-13 44.15
B5-6 30.65 H3-3 38.45 A4-1 42.5
B5-7 29.15 H3-4 39.45 A4-2 45.4
B5-8 32.2 H3-5 26.5 A4-3 44.55
B5-9 31.25 H3-6 38.9 A4-4 44.8
B5-10 34.85 H3-7 42.1 A4-5 42.05
B5-11 31.25 H3-8 38.7 A4-6 42.25
B5-12 31.9 H3-9 34.35 A4-7 42
B5-13 31.1 H3-10 38.15 A4-8 44.65
B5-14 24.95 H3-11 38.45 A4-9 45.8
D1-1 39.6 H3-12 40.9 A4-10 41.9
D1-2 38.6 H3-13 37.15 A4-11 44.3
D1-3 37.2 H3-14 37.7 A4-12 46.25
D1-4 39.2 H3-15 40 A4-13 41.35
D1-5 33.9 H3-16 36.35 E5-1 40.5
D1-6 34.2 H3-17 37.85 E5-2 41.6
D1-7 40.1 H3-18 38.6 E5-3 38.1
D1-8 38.8 C5-1 37.7 E5-4 40.1
D1-9 38.75 C5-2 37.5 E5-5 40.45
D1-10 37.65 C5-3 38.45 . E5-6 40.75
D1-11 42.2 C5-4 36.4 E5-7 38.95
C5-5
SUM 1910.6 C5-6
AVE 38.212 C5-7
STDEV 5.691 C5-8
C5-9
C5-10
C5-11
C5-12
C5-13
D5-1
D5-2
D5-3
D5-4
D5-5
D5-6
D5-7
D5-8
D5-9
D5-10
D5-11
D5-12
D5-13
G1-1
G1-2
G1-3
G1-4
G1-5
G1-6
G1-7
G1-8
G1-9
G1-10
G1-11
G1-12
G1-13
G1-14
G1-15
G1-16
G1-17
3GJhe effect of creatine devel<swS5at foetus
36.85 E5-9 39.6
36.15 E5-10 38.95
37.25 E5-11 38.4
36.35 E5-12 41.45
36.2 11-1 32.15
35.5 11-2 39.6
33.95 11-3 36.55
35.05 11^ 40.00
40.1 11-5 34.95
39.55 11-6 38.9
41.25 11-7 37.35
27.9 11-8 36.2
36.4 11-9 36.15
39.2 11-10 38.75
37.85 11-11 32.45
39.05 11-12 39.15
37.8
39.65 SUM 2719.95
39.4 AVE 40.596
40.15 STDEV 3.430
41.6
35.5 
38.25 
40.65 
41.20
36.75
38.85 
37.9
35.8 
40
38.7
38.6
37.6 
36.45
40.75
36.85
38.9 
40.2
SUM 3426.22 
AVE 38.497
STDEV 2.766
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Group B (day 9 and day 11 injection)
Foetus nr Control B Foetus nr Exper. B1 Foetus nr Exper. B2
Saline ri5q/davl r30q/davl
B3-1 35.3 E4-1 37.15 B1-1 37.15
B3-2 38.9 E4-2 38.65 B1-2 38.6
B3-3 39.7 13-1 38.15 B1-3 37.25
B3-4 37.2 C2-1 34.8 B1-4 36.5
B3-5 37 C2-2 36.45 B1-5 38.4
B3-6 41.4 C2-3 38.7 B1-6 36.3
B3-7 39.5 C2-4 29.05 B1-7 39.45
B3-8 38.3 C2-5 34.8 B1-8 38.8
B3-9 38.55 C2-6 36 B1-9 39.45
B3-10 40.4 C2-7 33.6 B1-10 38.3
B3-11 40 C2-8 38 B1-11 35.1
B3-12 38.8 G2-1 32.9 14-1 38.05
B3-13 38.4 G2-2 35.2 I4-2 38.75
H2-1 37.15 G2-3 34.15 I4-3 39.1
F3-1 35.1 G2-4 36.35 I4—4 42.8
F3-2 35.4 G2-5 35.3 C4-1 35.75
F3-3 40.55 G2-6 27.8 C6-1 37.95
F3-4 38.8 G2-7 39 C6-2 38.25
F3-5 39.8 G2-8 35.5 C6-3 38.05
F3-6 34.8 G2-9 35.15 C6-4 37.85
F3-7 42.6 G2-10 37.35 C6-5 41.05
F3-8 38.4 G2-11 38 C6-6 39.15
F3-9 37.8 G2-12 33.5 C6-7 39.6
F3-10 36.95 B4-1 35.4 C6-8 34.25
F3-11 33.3 H4-1 44.4 C6-9 39.9
F3-12 41 H4-2 43.65 C6-10 36.4
D4-1 44.7 H4-3 45.4 C6-11 34.8
D4-2 44.85 H4-4 42.95 C6-12 40.1
D4-3 49.2 H4-5 46.85 C6-13 37.25
D4-4 44.25 H4-6 45.7 C6-14 42.8
D4-5 44.05 H4-7 42.4
D4-6 47 H4-8 44.6 SUM 1147.15
D4-7 46.15 H4-9 43.5 AVE 38.238
D4-8 47.1 H4-10 41.9 STDEV 2.036
D4-9 46.6 H4-11 44.15
D4-10 47.45 H4-12 44.4
D4-11 47.35 H4-13 35
D4-12 48.7 H4-14 41.6
G5-1 31.9 A6-1 32.5
H5-1 38.1 A6-2 28.85
H5-2 39.7 A6-3 26.05
H5-3 39.9 A6-4 31.55
H5-4 39.5 A6-5 34.6
A6-6 28.5
SUM 1741.6 A6-7 30.75
AVE 40.502 A6-8 30
STDEV 4.344 A6-9 29.65
A6-10 29.45
A6-11 30.55
A6-12 30.4
15-2 40.75
15-3 39.25
15-4 37
15-5 41.5
15-6 41.25
15-7 42.5
15-8 40.15
15-9 42.400
15-10 39.9
15-11 38.8
SUM 2264.75
AVE 37.127
STDEV 5.242
15-1 40.95 effect of creatine on the developing rat foetus
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WEIGHT OF F Q E T U S ^S ^ffg fifrg f creatine on the developing rat foetus
Group A (day 7-13 consecutive injections)
Foetus nr Control A Foetus nr Exper. A1 Foetus nr Exper. A2
Saline ri5q/davl r30a/davl
E1-1 3.25 A1-1 6.39 G3-1 4.34
E2-1 6.7 A1-2 6.18 G3-2 3.72
E2-2 6.04 A1-3 5.91 G3-3 4.31
E2-3 6.17 A1-4 5.62 F1-1 3.87
E2-4 6.02 A1-5 4.65 F1-2 2.92
E2-5 6.57 A1-6 5.94 F1-3 4.4
E2-6 6.04 A1-7 6.21 F1-4 4.53
E2-7 6.08 A1-8 6.3 F1-5 3.77
E2-8 4.3 A1-9 5.47 F1-6 4.06
E2-9 6.81 A1-10 5.84 F1-7 4.8
E2-10 6.38 A1-11 5.69 F1-8 4.18
E2-11 6.59 E3-1 4.28 F1-9 4.21
E2-12 6.38 E3-2 4.17 F1-10 3.52
A5-1 4.8 E3-3 4.56 F1-11 4.41
A5-2 4.76 E3-4 4.56 F1-12 4.56
A5-3 4.32 E3-5 4.13 F1-13 3.32
A5-4 4.82 E3-6 4.35 F1-14 3.99
A5-5 4.83 E3-7 4.46 C3-1 6.36
A5-6 4.28 E3-8 4.25 C3-2 5.82
A5-7 5.35 E3-9 4.31 C3-3 5.07
A5-8 4.42 E3-10 4.19 C3-4 6.15
A5-9 4.81 E3-11 4.09 C3-5 5.61
A5-10 5.07 E3-12 4.77 C3-6 6.07
A5-11 4.6 E3-13 4.72 C3-7 5.88
A5-12 3.26 E3-14 4.68 C3-8 5.75
B5-1 2.51 E3-15 3.56 C3-9 6.5
B5-2 2.42 E3-16 4.21 C3-10 5.71
B5-3 2.56 E3-17 4.85 C3-11 4.95
B5-4 2.59 H3-1 3.67 C3-12 5.75
B5-5 2.52 H3-2 4.74 C3-13 5.79
B5-6 2.32 H3-3 4.05 A4-1 6.08
B5-7 2.09 H3-4 4.47 A4-2 6.61
B5-8 2.56 H3-5 2.05 A4-3 6.64
B5-9 2.75 H3-6 4.02 A4-4 5.92
B5-10 2.74 H3-7 4.54 A4-5 5.94
B5-11 2.68 H3-8 4.15 A4-6 4.97
B5-12 2.72 H3-9 2.72 A4-7 6.02
B5-13 2.45 H3-10 3.89 A4-8 5.94
B5-14 1.98 H3-11 4.15 A4-9 6.28
D1-1 4.5 H3-12 4.47 A4-10 4.75
D1-2 4.11 H3-13 3.90 A4-11 5.76
D1-3 3.6 H3-14 4.08 A4-12 6.41
D1-4 4.39 H3-15 4.18 A4-13 7.62
D1-5 2.65 H3-16 3.39 E5-1 4.23
D1-6 2.77 H3-17 4.24 E5-2 4.63
D1-7 4.73 H3-18 4.18 E5-3 3.88
D1-8 4.55 C5-1 4.12 E5-4 4.2
D1-9 4.04 C5-2 3.87 E5-5 3.93
D1-10 5.41 C5-3 3.88 . E5-6 4.35
D1-11 6.67 C5-4 3.71 E5-7 4.26 J22
C5-5
SUM 214.96 C5-6
AVE 4.299 C5-7
STDEV 1.507 C5-8
C-DENCE 0.418 C5-9
C5-10
C5-11
C5-12
C5-13
D5-1
D5-2
D5-3
D5-4
D5-5
D5-6
D5-7
D5-8
D5-9
D5-10
D5-11
D5-12
D5-13
G1-1
G1-2
G1-3
G1-4
G1-5
G1-6
G1-7
G1-8
G1-9
G1-10
G1-11
G1-12
G1-13
G1-14
G1-15
G1-16
G1-17
4 n  The effect of creatine&QJ$e develoRii^rat foetus
3.82 E5-9 4.56
3.75 E5-10 4.26
3.95 E5-11 4.08
3.98 E5-12 4.48
3.56 11-1 3.5
3.95 11-2 4.27
2.92 11-3 4.58
4.01 11-4 4.13
4.40 11-5 3.23
4.68 11-6 3.91
4.45 11-7 4.37
2.08 11-8 3.44
4.44 11-9 3.75
4.13 11-10 4.1
4.34 11-11 2.68
4.46 11-12 4.71
4.53
4.21 SUM 321.42
4.29 AVE 4.797
4.34 STDEV 1.056
4.53
4.19
4.3
4.13
4.38
3.8
4.45
4.32 
4.05
4.46 
4.07 
4.09
4.32 
3.94
4.33 
4.11
3.8 
4.26
SUM 384.74
AVE 4.323
STDEV 0.754
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Group B (day 9 and day 11 injection)
Foetus nr Control B Foetus nr Exper. B1 Foetus nr Exper. B2
Saline n5q/dayl r30q/davl
B3-1 4.11 E4-1 3.94 B1-1 3.89
B3-2 4.36 E4-2 3.65 B1-2 4.22
B3-3 4.2 13-1 3.53 B1-3 4.2
B3-4 3.92 C2-1 3.44 B1-4 4.23
B3-5 4.09 C2-2 4.02 B1-5 4.15
B3-6 4.58 C2-3 4.11 B1-6 4.02
B3-7 4.22 C2-4 2.1 B1-7 4.32
B3-8 3.83 C2-5 3.18 B1-8 4.58
B3-9 4.31 C2-6 3.37 B1-9 4.36
B3-10 4.09 C2-7 3.57 B1-10 4.28
B3-11 3.96 C2-8 3.83 B1-11 4.05
B3-12 4.16 G2-1 3.41 14-1 3.34
B3-13 4.17 G2-2 3.29 I4-2 3.92
H2-1 3.65 G2-3 3.15 I4-3 4.04
F3-1 4.06 G2-4 3.68 I4—4 7.6
F3-2 3.91 G2-5 3.46 C4-1 3.24
F3-3 3.89 G2-6 2.28 C6-1 3.99
F3-4 4.32 G2-7 3.77 C6-2 3.86
F3-5 3.52 G2-8 3.35 C6-3 4.31
F3-6 3.39 G2-9 3.65 C6-4 4.52
F3-7 4.25 G2-10 3.68 C6-5 4.53
F3-8 4.2 G2-11 3.81 C6-6 4.17
F3-9 4.13 G2-12 3.55 C6-7 4.42
F3-10 3.88 B4-1 3.54 C6-8 3.56
F3-11 3.44 H4-1 6.53 C6-9 4.33
F3-12 4.46 H4-2 6.06 C6-10 3.83
D4-1 7.66 H4-3 6.56 C6-11 3.37
D4-2 6.87 H4-4 6.33 C6-12 4.49
D4-3 7.72 H4-5 6.62 C6-13 3.91
D4-4 5.76 H4-6 8.67 C6-14 4.39
D4-5 5.86 H4-7 5.88
D4-6 6.65 H4-8 6.18 SUM 126.12
D4-7 7.46 H4-9 5.95 AVE 4.204
D4-8 6.99 H4-10 5.92 STDEV 0.732
D4-9 7.26 H4-11 6.01
D4-10 7.55 H4-12 6.21
D4-11 6.94 H4-13 3.42
D4-12 7.28 H4-14 4.54
G5-1 3.26 A6-1 2.72
H5-1 3.62 A6-2 2.19
H5-2 4.25 A6-3 2.29
H5-3 4.02 A6-4 2.74
H5-4 4.87 A6-5 2.76
A6-6 2.25
SUM 209.12 A6-7 2.61
AVE 4.863 A6-8 2.52
STDEV 1.417 A6-9 2.09
A6-10 2.44
A6-11 2.44
A6-12 2.88
15-1 6.63
15-2 4.21
15-3 4.1
15-4 4.08
15-5 4.13
15-6 4.65
15-7 4.49
15-8 4.23
15-9 4.28
15-10 3.82
15-11 4.41
SUM 247.2
AVE 4.052
STDEV 1.438
The effect of creatine on the developing rat foetus
125
of
 cr
ea
tin
e 
on
 th
e 
de
ve
lo
pi
ng
 ra
t f
oe
tu
s
\D C' \
F O E TU S  W E IG H T  IN A L L  G R O UPS
1 9 17 25 33 41 49 57 65 73 81 89
AM O UNT OF FOETUSES
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A M O U N T  O F  E M B R Y O S  V S  R E S O R B E D  E M B R Y O S  IN E A C H  G R O U P
7 D A Y S  C O N S E C U T I V E L Y  D A Y  9 A N D  11 INJECTIONS
SALINE 15G 30G SALINE 15G 30G
A 2 A1 A4 B3 B4 B1
PP 11E 13E+3R 13E 1E+5R 11E
D1 C1 C3 D4 C2 C4
11E PP 13E 12E 8E+1R 1E+7R
E1 E3 F1 F3 E4 F2
1E+2R 17E 14E 12E 2E+7R 9L+2R
E2 G1 G3 F4 G2 G4
12E 17E+1R 3E+5R 7R 12E+1R 8R
H1 H3 11 H2 H4 I2
8R 18E 12E+3R 1E+4R 14E+1R 11R
A5 C5 E5 G5 I3 I4
12E+2R 13E+2R 12E 1E+7R 1E+7R 4E+6R
B5 D5 F5 H5 I5 B6
14E+1R 13E PP 4E+13R 11E PP
A6 C6
12E+2R 14E+2R
50E+13R 89E+3R 67E+11R 43E+31R 61E+24R 30E+34R
50 89 67 43 61 30
13 3 11 31 24 34
SURVIVING FOETUSES VS 
ABSORBED FOETUSES
■ Surviving 
foetuses
■ Absorbed 
foetuses
12 7
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
7
7
7
7
7
DISTRIBUTION NUMBERS The effect of creatine on the developing rat foetus
WEIGHT LENGTH
A1 A2 CB B1 B2 CA A1 A2 CB B1 B2
2 3 3 2 3 25 27 32 32 26 34
2 3 3 2 3 28 28 32 33 28 35
3 3 3 2 3 29 34 35 35 29 35
3 3 4 2 4 30 34 36 35 29 36
3 3 4 2 4 31 34 36 35 29 36
4 4 4 2 4 31 35 36 35 29 36
4 4 4 2 4 31 36 36 37 30 37
4 4 4 2 4 31 36 37 37 30 37
4 4 4 3 4 31 36 37 37 30 37
4 4 4 3 4 32 36 37 37 31 37
4 4 4 3 4 32 36 37 38 31 38
4 4 4 3 4 32 36 37 38 32 38
4 4 4 3 4 32 36 38 38 33 38
4 4 4 3 4 34 36 38 38 33 38
4 4 4 3 4 34 36 38 38 34 38
4 4 4 3 4 35 36 38 39 34 38
4 4 4 3 4 35 36 38 39 34 38
4 4 4 3 4 37 36 38 39 35 39
4 4 4 3 4 37 37 39 39 35 39
4 4 4 3 4 38 37 39 40 35 39
4 4 4 3 4 39 37 39 40 35 39
4 4 4 3 4 39 37 39 40 35 39
4 4 4 3 4 39 37 39 40 35 39
4 4 4 4 4 39 37 39 40 35 39
4 4 4 4 4 39 38 39 40 35 40
4 4 4 4 4 39 38 39 40 36 40
4 4 4 4 5 40 38 39 40 36 40
4 4 4 4 5 40 38 39 41 36 41
4 4 4 4 5 40 38 39 41 36 43
4 4 5 4 8 40 38 40 41 37 43
4 4 5 4 41 38 40 43 37
4 4 6 4 41 38 40 44 37
4 4 6 4 41 38 40 44 38
4 5 7 4 41 38 40 45 38
4 5 7 4 42 38 40 45 38
4 5 7 4 42 38 41 46 39
4 5 7 4 42 38 41 47 39
4 5 7 4 42 38 41 47 39
4 5 7 4 43 38 41 47 39
4 5 7 4 43 38 41 47 39
4 5 8 4 43 38 41 47 40
4 5 8 4 44 38 41 49 40
4 5 8 4 44 38 42 49 41
4 5 4 44 39 42 41
4 5 4 45 39 42 41
4 6 4 46 39 42 42
4 6 5 47 39 42 42
4 6 5 47 39 42 42
4 6 6 47 39 42 42 .
4 6 6 47 39 43 42 128
6
6
6
6
6
6
6
6
6
6
6
6
6
7
7
7
8
6
6
6
6
6
6
7
7
7
7
9
39
39
39
39
39
39
39
39
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40
40
41 
41 
41 
41 
41 
41 
41
41
42 
42 
42 
42 
42
42
43 
43 
43
43
44
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44 43
44 44
44 44
44 44
45 44
45 44
45 45
45 45
45 46
45 47
46
46
46
46
47
48
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NORMAL DISTRIBUTION AND CHI-TEST DERIVED FROM FOETAL WEIGHT
CA A1 A2 CB B1 B2
OB EX OB EX OB EX OB EX OB EX OB EX
GRAM
2 5 4 2 1 8 6 3 6
3 13 9 3 11 5 6 3 5 15 13 23 14
4 8 13 62 42 28 18 26 10 23 16 3 8
5 12 12 13 30 12 23 2 12 2 13
6 7 8 9 4 18 14 2 9 8 7
7 5 3 3 0 7 4 4 3
8 1 1 3 1 1 0
9 1 0
CHI TE ST 3.5 17.04 13.8 44.15 13.7 8.32
NORMAL DISTRIBUTION AND CHI-TEST DERIVED FROM FOETAL LENGTH
CA A1 A2 CB B1 B2
OB EX OB EX OB EX OB EX OB EX OB EX
MM
27 3 2 2 0 6 4
32 12 10 3 8 2 3 2 2 11 14 1 1
37 11 17 53 52 27 23 17 14 23 23 23 25
42 18 14 31 28 26 32 14 19 17 15 6 5
47 6 5 12 9 10 7 4 4
CHI TEST 3.98 1.12 2.37 3 0.13 0.29
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